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Abstract 
 
KEITH RUSSELL MILLER:  Use of T Cell Receptor-like Antibody Fragments for 
Imaging and Immunotherapy  
(Under the direction of Edward J. Collins) 
 
 
The cellular proteome, in both healthy and diseased cells, is presented on the 
cell membrane surface as peptides bound to the major histocompatibility complex 
(pMHC).  During disease, the interaction of specific disease associated pMHC with T 
cell receptors (TCR) expressed on CD8+ cytotoxic T cells allows the priming and 
activation of the immune system.  Thus, the immune system can actively identify and 
kill diseased cells by recognition of the pMHC on the diseased cells’ surface.  
Sometimes non-disease associated pMHC are misidentified on healthy cells, which 
are attacked leading to autoimmune disease.  The association of the pMHC 
molecule with infection, cancer, and autoimmunity has made the pMHC a valuable 
target for immunotherapeutic development.  In order to identify disease-associated 
pMHC molecules, high affinity antibodies endowed with TCR-like specificity have 
been developed as a novel means to target tumor and virus-infected cells and for 
studying autoimmune disease.  
Our goal is to improve disease treatment by using TCR-like antibody 
fragments (Fabs) that mimic the specificity of a TCR to study cancer and 
autoimmune Type 1 Diabetes (T1D).  Using our phage-displayed derived TCR-like 
Fabs, we show specific identification of both human tumors and beta cells in mice.  
Specifically, one Fab, fE75, binds to the human epidermal growth factor Receptor 2 
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peptide, E75, bound to the MHC called Human Leukocyte Antigen-A2 expressed on 
many human cancer cells.  fE75 binding improved in vivo imaging of human tumors 
in a tumor mouse model.  Translation of such technology into the clinic may 
revolutionize how cancer is monitored and treated.  Another Fab, fIGRP, binds the 
islet-specific glucose-6-phosphatase catalytic subunit-related protein peptide (IGRP), 
restricted to the MHC, histocompatibility-2 Kd (H-2Kd).  IGRP peptide-bound H-2Kd is 
expressed on beta cells in the nonobese diabetic mouse model.  Using fIGRP, we 
show that the Fab specifically localizes to beta cells in mouse pancreas and can 
prevent activation of autoimmune T cells.  Thus, TCR-like Fabs have the potential to 
protect against T1D onset and be developed for targeted therapies for beta cell 
recovery.  The ability to generate TCR-like Fabs has vast potential for studying 
antigen presentation in cancer, viral infections, and autoimmunity and for targeted 
therapeutics.  
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Chapter 1 
A review of T cell receptor-like antibodies 
 
1.1  Introduction 
 
 Over 100 years ago, Paul Ehrlich, the German physician and scientist, first 
proposed the idea of antibodies as “magic bullets” that not only activate effective 
immune system responses, but also can be used to deliver drugs or toxins to 
disease sites.  Now, antibodies are commonly used to treat a variety of diseases 
including cancer (1).  One of the most successful examples is the use of monoclonal 
antibodies directed against the Human Epidermal Growth Factor Receptor-2 
(HER2/neu) for the treatment of breast cancer (2).  These antibodies can interfere 
with signals generated by the bound receptor and deliver conjugated drugs to the 
tumor cells.  The use of antibodies for treatment relies on cell surface expression of 
antigens specific for the cancer or diseased cell.  Examples include Cetuximab, 
targeting epidermal growth factor receptor in colorectal and head and neck cancer; 
Rituximab, targeting CD20 in Non-Hodgkin lymphoma; and Trastuzumab, binding 
epidermal growth factor receptor, ErbB2, in breast cancer (1,2).  Even though there 
are hundreds of clinical trials using such monoclonal antibodies, the number of 
known antigens exclusively found on the surface of diseased cells is limited.  Thus, 
there is a significant need for markers that distinguish infected or cancerous cells 
from endogenous healthy cells based on the extracellular and intracellular proteome 
(3).   
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 The immune system differentiates infected or cancerous abnormal cells from 
endogenous normal healthy cells via the Major Histocompatibility Complex (MHC) 
class I molecules.  These MHC molecules are expressed constitutively on the 
surface of all nucleated cells and function to present peptides from proteins 
synthesized within the cell.  Eight to twelve amino acid long peptides derived from 
proteasome-degraded proteins are bound to the MHC in the endoplasmic reticulum 
and presented on the surface of the cell.  Thus, the peptide-bound MHC (pMHC) 
provides a view of the intracellular protein content of the cell; if the cell becomes 
abnormal, the proteins that are translated are abnormal, the peptides produced by 
proteasomal degradation are abnormal, and the composition of peptide then 
presented by the MHC are abnormal.  Similarly, the distribution of peptides 
presented by MHC on a heart cell is different from the population of peptides 
presented by a beta cell.  This process results in a display of cell-specific antigens 
on the cell surface that could be detected.  Instead of antibodies, the immune 
system has cytotoxic T lymphocytes (CTLs) that recognize viral, tumor, or abnormal 
peptides presented by the MHC.  Upon binding of the disease-associated pMHC 
with the CTLs T cell receptor (TCR), the CTLs are activated to kill the cancerous or 
diseased cells and to recruit other immune cells to the site of disease.  The ability of 
the pMHC presentation system to present an extracellular representation of the inner 
proteome of the cell provides a mechanism for the immune system to distinguish 
and target diseased cells with high sensitivity (4).  Therefore, pMHC molecules are 
an exciting potential target for antibodies to detect diseased/abnormal cells for 
targeted therapeutics. 
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1.2  Identification of disease associated peptide/MHC class I molecules  
 
 Before antibodies against pMHC are generated, disease associated pMHC 
molecules must be identified.  There are two main approaches, indirect and direct 
discovery, for identifying peptides associated with MHC molecules.  Indirect 
discovery relies on genomic, proteomic, or immunologic data to predict the peptides 
that are bound to particular MHC molecules in a variety of diseases (5).  Often, it is 
assumed that proteins that are over-expressed as a result of a disease state will be 
over-represented as pMHC molecules on the surface of diseased cells.  Following 
identification of disease-associated genes and proteins, algorithms and/or 
computational modeling peptide binding assays are used to identify theoretically 
high binding affinity peptides for the MHC.  These identified peptides are then 
synthesized and tested in vitro for MHC binding and/or activation of a CTL response 
(6).  Direct discovery methods for identifying disease-associated pMHC molecules 
rely on peptides elution from pMHC complexes purified from diseased cell lysate.  
The primary sequence of the peptides is determined by mass spectrometry (7). 
 Both indirect and direct peptide binding MHC identification approaches have 
limitations.  The indirect methods suffer from relying on computational algorithms 
and selection criteria based on assumptions that may be wrong.  Moreover, even 
though it is logical that highly over-expressed proteins should be over-represented 
on pMHC molecules, this is not necessarily always the case.  The peptide 
processing and presentation pathways have numerous moving parts resulting in 
greater difficulty in predicting how and whether highly expressed viral or tumor 
associated proteins will even be presented by MHC molecules.  Because of these 
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limitations, indirect discovery methods may not uncover main disease associated 
pMHC or give false positive hits for irrelevant pMHC molecules.  In direct discovery 
methods, the peptides eluted are often from cell lines, which can provide their own 
bias to peptide discovery.  Moreover, this technique of direct purification of peptides 
relies on the solubility and ionization potential of the given peptides.  It is assumed 
that peptides with high hydrophobicity and/or poor ionization are not detected by 
direct discovery.  Thus, both indirect and direct discovery methods have their own 
technical issues, but these methods provide starting points for identifying disease-
associated pMHC molecules upon careful validation (6).    
1.3  Generation of TCR-like antibodies 	  
The use of CTL TCR for targeting disease-associated pMHC has been 
attempted by numerous approaches, but has ultimately failed as a reliable research 
tool.  Genetically engineered T cells expressing only one TCR have been used to 
indirectly assess pMHC molecules via cell lysis and cytokine assays and CTL 
proliferation assays with varied success.  The maintenance of such cell lines is 
costly and labor intensive with the added difficulty of quality control.  Therefore, 
interest in using soluble TCRs as reagents grew, but recombinant TCRs had issues 
including:  low affinities (high micromolar) and limited stability (8-14).  Both of these 
issues were addressed by multimerization of the TCRs and protein engineering for 
improved affinity and stability (15, 16).   
 Antibodies and antibody fragments specific for pMHC molecules provide 
numerous advantages over TCRs as soluble and specific reagents.  First and 
foremost, they have higher affinities than TCRs and provide greater stability. TCR-
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like antibodies can be used under a variety of different assay conditions including:  
immunoprecipitations and immunohistochemistry.  Unfortunately, TCR-like 
antibodies have been difficult to make due to unknown reasons, but several have 
been produced by either classical hybridoma fusion technology after immunization or 
by phage display (3, 6).  A list of isolated and tested TCR-like antibodies/antibody 
fragments is given in Table 1.  
In the immunization and classical hybridoma technology approach for 
isolating TCR-like antibodies, B cells from antigen-immunized animals are fused with 
myeloma cells to create an antibody-producing hybridoma.  Most attempts at using 
this technology have failed (17-19).  Although there are a few groups that have been 
successful (20, 21).  The success of these few instances is hypothesized to be due 
to the efficiency in inducing a specific B cell response during the immunization.  This 
relies heavily on the pMHC immunogen formulation, which should be stable, 
homogeneous, and induce antibody responses to both peptide and the MHC 
combined instead of either alone (6).  Initially, cells expressing the pMHC of interest 
were used as immunogens resulting in approximately one to three out of 
approximately 1000 growth-positive clones able to produce TCR-like antibodies 
specific for the target pMHC (22, 23).  The use of recombinant purified pMHC class I 
molecules as immunogens showed successful production of monoclonal antibodies 
with affinities that were ten-fold higher than TCRs (24).  The efficiency of this 
technique at 0.5% and the only moderate affinity of the antibodies compared to 
TCRs left this technique as requiring further optimization before it could reliably be 
used as a source of TCR-like antibodies (6).    
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Table 1:  List of TCR-like Molecules and Their Associated Specificities 
 
MHC Peptide Disease Association Type 
Isolation 
Method 
KD 
(nM) Ref. 
HLA-A2 gp100-154 KTWGQYWQV Melanoma Fab 
Phage 
display 
15-
30 16 
HLA-A2 gp100-209 ITDQVPFSV Melanoma Fab 
Phage 
display 
15-
30 16 
HLA-A2 gp100-280 YLEPGPVTA Melanoma Fab 
Phage 
display 
15-
30 16 
HLA-A2 Tyrosinase-369 YMDGTMSQV Melanoma Ab 
Phage 
display ~50 17 
HLA-A2 Mart-1 LAGIGILTV Melanoma Ab 
Phage 
display ~50 17 
HLA-A2 MAGE-A1 EADPTGHSY 
Melanoma 
and solid 
tumors 
Fab Phage display 60 
18, 
19 
HLA-A2 MAGE3-271 FLWGPRALV 
Melanoma 
and solid 
tumors 
Ab Hybridoma 2.37 20 
HLA-A2 
p68 RNA 
helicase-128 
YLLPAIVHI 
Breast 
Cancer Ab Hybridoma 0.42 
21, 
22 
HLA-A2 NY-ESO-1-157  
Normal 
Testis and 
other tumors 
Fab Phage display 60 23 
HLA-A2 TARP-29 FLRNFSLML 
Breast and 
prostate 
cancer 
Fab Phage display 120 24 
HLA-A2 
human  
chorionic 
gonadotropin β 
GVLPALPQV 
Ovarian, 
colon and 
breast 
cancer 
Ab Hybridoma 1.5 25 
HLA-A2 HER2/neu-369 KIFGSLAFL 
Ovarian, 
colon and 
breast 
cancer 
Fab 
Native 
phage 
dispay 
59 26 
HLA-A2 
human  
chorionic 
gonadotropin β 
TMTRVLQGV 
Ovarian, 
breast, and 
other 
cancers 
 
Ab Hybridoma n/a 27 
HLA-A2 PR1 VLQELNVTV Leukemia Ab Hybridoma 9.9 28 
HLA-A2 TAX-11 LLFGYPVYV HTLV-1 Fab 
Phage 
display 
25-
30 29 
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MHC Peptide Disease Association Type 
Isolation 
Method 
KD 
(nM) Ref. 
HLA-A2 MUC-1-D6-13 LLLTVLTVV 
Glandular 
cancer Fab 
Phage 
display 
15-
25 29 
HLA-A2 Telomerase-540 ILAKFLHWL 
Most human 
cancers Fab 
Phage 
display ~5 30 
HLA-A2 Telomerase-865 RLVDDFLLV 
Most human 
cancers Fab 
Phage 
display 
10-
15 30 
HLA-A2 SSX2-103 RLQGISPKI 
Normal 
Testis and 
melanoma 
Fab Phage display 270 31 
HLA-A2 M1-58 GILGFVFTL Influenza Fab 
Phage 
display n/a 32 
HLA-A2 Nef-105 KRQDILDLWVY HIV-1 Ab 
Phage 
display 4 33 
HLA-A2 ENV-183 FLLTRILTI EBV Ab Hybridoma n/a 34 
HLA-A2 eIF4G-720 VLMTEDIKL HIV-1 Ab Hybridoma n/a 35 
HLA-A2 Nef138-10/A24 RYPLTFGWCF HIV-1 Ab 
Phage 
display 2700 36 
HLA-A2 pp65-495 NLVPMVATV CMV Ab 
Phage 
display 300 37 
I-Ak 
HEL46 
NTDGSTDYGIL
QINSR 
n/a Ab Hybridoma n/a 38, 39 
I-Ak 
HEL116 
KGTDVQAWIRG
CRL 
n/a Ab Hybridoma n/a 40 
HLA-
DR2 
MOG-35-55 
MEVGWYRPPF
SRVVHLYRNGK 
Multiple 
Sclerosis Ab 
Phage 
display 
30-
60 41 
H-2Kb Ovalbumin SIINFEKL n/a Ab Hybridoma 256 41 
H-2Kk HA255 FESTGNLI Influenza Ab 
Phage 
display 56 
42, 
43 
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The major advancement for isolation of TCR-like antibodies was the 
development of antibody phage-display approaches as an alternative to classical 
hybridoma technologies.  This technology utilizes phage particle libraries expressing 
antibodies as fusion proteins on their surface.  One unique antibody fragment or 
single-chain variable fragment is displayed on each phage particle and is encoded 
by the phage genes.  Repeated rounds of selection using magnetic beads displaying 
the pMHC molecules followed by bacterial amplification are used to isolate phage 
expressing antibody-derived molecules specific for pMHC (25-28).  Using this 
methodology, high affinity TCR-like antibody-derived molecules have been 
produced.  These molecules generally have low affinity, but can be genetically-
engineered for higher affinity for their target pMHC molecule.  Random and rational 
affinity maturation strategies have been reported to increase binding affinities of 
phage-display isolated TCR-like antibody-derived molecules into the nanomolar 
range (~50-300 nM) (29, 30).  Therefore, large phage-display libraries are now the 
method of choice and the most common approach for isolating TCR-like antibody-
derived molecules. 
1.4  TCR-like antibody applications 	  
TCR-like antibodies have great potential to be valuable tools for 
understanding immunological processes and for the development of novel 
therapeutics.  Their ease of use, specificity, and sensitivity makes them very 
versatile for research assays.  Applications of such reagents include:  monitoring 
and quantifying antigen presentation on diseased cells and comparing it to 
endogenous healthy cells, understanding the importance of pMHC molecules for 
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immune responses, targeted delivery of toxins to sites of disease or infection, and 
activation of effective immune responses against tumors (3, 6).   
TCR-like antibodies are novel reagents that may expand the tool set 
immunologists use to monitor and quantify antigen presentation during disease.  The 
small set of available antibodies have been used to determine the presence of 
particular pMHC on cancer cells (27, 31-34).  Moreover, methods for quantifying 
levels of specific pMHC on cell surfaces by flow cytometry are being developed (35).  
Using these and similar methods, TCR-like antibodies have quantified that there are 
several hundreds of specific pMHC complexes on non-peptide pulsed cancer cells 
(32).  This number is in agreement with estimates on the level of pMHC density 
required for CTL activation and lysis (36, 37).  In other studies, an expression 
hierarchy of T cell epitopes from melanoma antigens was analyzed.  Analysis of 
pMHC expression levels of human gp100, Melan-A/Mart-1, and tyrosinase antigen 
showed that there was high level of tyrosinase derived pMHC molecules on the 
surface of melanoma compared to the other antigens.  It was determined that the 
quantity of the melanoma pMHC antigens did not correlate with the gene expression 
profiles.  Moreover, melanoma cells given a drug that stabilizes tyrosinase showed a 
decrease in the tyrosinase antigen derived pMHC levels.  Thus, it was hypothesized 
that protein stability was the dominating factor resulting in the differences between 
the antigens in their antigen presentation (34).  In addition, TCR-like antibodies have 
been shown to aid in developing cancer vaccines.  In one example, TCR-like 
antibodies specific for peptides derived from the NY-ESO-1 protein were used to 
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differentiate between the CTL reactivity to immunological eliciting NY-ESO-1 
vaccination peptides compared to cryptic, nonimmune responsive peptides (33).   
The specificity of some TCR-like antibodies for cancer pMHC molecules 
makes them promising agents to deliver toxins to the cancer cells or as antitumor 
agents in themselves. TCR-like antibodies fused to Pseudomonas exotoxin (38-40) 
and saporin (41) are effective at killing cancer cells in vitro and in vivo.  These TCR-
like antibodies fused to toxins specifically identified and killed a variety of cancer 
cells including: prostate (40), breast (41), and melanoma (38, 39).  In addition, TCR-
like antibodies can induce effective immune responses against tumors without use of 
toxins.  Full TCR-like antibodies with Fc domains can elicit complement-dependent 
cytotoxicity (CDC) and activate antibody-dependent cellular cytotoxicity (ADCC) of 
cancer cells.  Activation of any of these immune responses leads to inhibition of 
tumor growth in mouse models injected with the TCR-like antibodies (21, 42-45).   
Alternatively, it has become possible to engineer T cells to attack cancer by 
transfection of T cells with viruses encoding chimeric antibody T cell receptors 
(CARs) consisting of a tumor specific antibody fused to an intracellular signaling 
domain able to activate T cells.  Often, these CARs consist of an extracellular single 
chain variable fragment of a monoclonal antibody fused to a co-stimulatory signaling 
domain such as CD28 and an intracellular CD3 zeta chain (46).  By using TCR-like 
antibodies, the specificity of T cells can be engineered against certain disease-
associated pMHC molecules.  In one example, T cells were designed to display 
chimeric receptors of the TCR-like Fabs fused to the FcεRI γ-chain signaling 
molecule.  Increased sensitivity, faster cytotoxic responses, and enhanced tumor cell 
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killing capacity were observed for these engrafted T cells (29). All together, these 
results demonstrate that TCR-like antibodies specific for tumor antigens can be 
isolated and effectively deliver drugs, kill tumors directly and may be used to 
engineer autologous T cells for immunotherapy.   
TCR-like antibodies have been used to understand antigen presentation 
during viral infection and to specifically target virally infected cells for therapy.  TCR-
like antibodies have been isolated against viral pMHC presented on cells infected 
with human immunodeficiency virus (HIV) (47, 48), influenza (49, 50), 
cytomegalovirus (51), human T cell lymphotropic virus type I (HTLV-1) (52), and 
Hepatitis B virus (HBV) (20, 53).   One TCR-like antibody, specific for the HTLV-1-
derived Tax11-19 peptide bound to HLA-A2, detected pMHC complexes as low as 100 
complexes per cell (52).  This is near the threshold number of pMHC molecules 
required for cytokine secretion by T cells (54, 55).  Thus, TCR-like antibodies can be 
isolated that have similar if not greater sensitivity for pMHC than T cells.  The 
dynamics of antigen presentation during viral infection have been studied using 
TCR-like antibodies.  In one study, a TCR-like antibody was used to show that the 
majority of viral antigen pp65 protein bound to HLA-A2 molecules during early 
infection were localized to the Golgi with only a small portion expressed on the cell 
surface (51).  This information provides further understanding of the complex events 
leading to viral antigen presentation.  The TCR-like antibody allowed for the direct 
visualization, distribution, and localization of the cytomegalovirus-derived peptide 
associated MHC during viral infection.  Finally, TCR-like antibodies targeting viral 
pMHC molecules have been used to kill infected cells.  Lentiviruses engineered to 
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display TCR-like antibodies and Fas ligand specifically killed HIV-1 Nef protein 
expressing cells.  In this study, the TCR-like antibody endowed the lentivirus with the 
specificity and the Fas ligand expression provided the lentivirus with the ability to kill 
based on the interaction between the Fas ligand and the Fas receptor on the 
targeted cells inducing apoptosis of the virally infected cells (47). Also, similar to the 
cancer therapies, TCR-like antibodies fused to toxins can kill influenza infected 
target cells in a pMHC specific manner.  In one example, a TCR-like antibody 
specific for the MHC class I H-2Kk bound to the virus-derived hemagglutinin peptide 
HA was fused with the Pseudomonas exotoxin, PE38.  This TCR-like antibody fused 
toxin specifically killed influenza virus-infec 
ted cells presenting the HA peptide bound H-2Kk molecule on their surface 
(49).  As a whole, TCR-like antibodies provide necessary tools to understand 
antigen presentation during infection and are versatile targeting probes for 
therapeutics. 
1.5  Conclusion 
 
 Disease either induced by genetic defects or by infection is often guided by 
intricate molecular mechanisms.  Molecules that function like TCR with pMHC 
specificity are a promising new technology that can probe fundamental elements of 
these processes.  Further work in the generation of TCR-like antibody-derived 
molecules is required to make the process more streamlined and easier to generate 
proteins with high affinity and specificity for pMHC. The few TCR-like antibody-
derived molecules that have been isolated do show promising results.  Several 
studies have shown that TCR-like antibodies can aid in understanding and revealing 
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important aspects of antigen processing and pMHC presentation mechanisms in 
cancer and virally infected cells.  Furthermore, these antibodies provide a new realm 
of targets for delivery of therapeutics to the sites of disease.  Our work discussed in 
this dissertation focuses on generating and utilizing TCR-like antibody fragments for 
in vivo xeno-transplanted tumor imaging for cancer treatment and 
imaging/immunotherapy of beta cells in type 1 diabetes.  We show that TCR-like 
antibody fragments with high affinity and specificity for their disease-specific pMHC 
molecule can be isolated and used as imaging agents and potential 
immunotherapeutics.  Therefore, TCR-like molecules may just be a “magic bullet” to 
assist in understanding MHC-based immunity and improving our use of 
immunotherapy in the future.   
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Chapter 2 
T cell receptor-like recognition of tumor in vivo by synthetic antibody 
fragment1 
 
2.1  Introduction 
 
One of the most important lessons learned about cancer in the past 100 years 
is the understanding that each cancer is as unique as the patient.  Effective 
treatment of the patient is linked to knowing which proteins, such as hormone 
receptors or HER2/neu, are actively expressed in the tumor.  Probes that allow us to 
ascertain the molecular details of each patient’s tumors will greatly enhance 
treatment.  Biopsies can be used to determine molecular details, but biopsy is 
invasive, not always possible and does not allow for the fact that the tumor may 
change characteristics over time or location [1].  It would be preferable to be able to 
perform a noninvasive technique first followed by treatment [2].  Our long-term goal 
is to develop agents that can specifically target tumor cells for detection and delivery 
of toxins or chemotherapeutics.  
Any noninvasive approach to determining molecular details of the tumor must 
use a probe that binds to the tumor cells with high affinity and high specificity.  
Monoclonal antibodies with affinity for cell-surface receptors on tumors have had 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1This chapter has been published as:  Miller, K. R., A. Koide, B. Leung, J. 
Fitzsimmons, B. Yoder, H. Yuan, M. Jay, S. S. Sidhu, S. Koide, and E. J. Collins. 
2012. T cell receptor-like recognition of tumor in vivo by synthetic antibody fragment. 
PLoS ONE 7: e43746. 
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great success in the clinic, but this approach appears to be limited because of the 
expression of that same cell surface receptor on normal cells that cause side effects 
during treatment.  One of the best examples of successful use of monoclonal 
antibodies to tumor-associated antigens is Herceptin.  Herceptin targets the human 
epidermal growth factor receptor 2 (HER2/neu).  HER2/neu is over-expressed in 15-
30% of solid tumors including breast, ovarian, colorectal, esophageal, squamous 
head and neck and stomach [3].  Over-expression of HER2/neu correlates with poor 
prognosis for therapy of breast cancer [4-8] and has been linked to increased 
metastases [9].  Monoclonal antibodies directed towards HER2/neu such as 
Herceptin have shown great efficacy in the clinic, but patients do develop resistance 
over time [10] and some patients do not respond at all [11].  Therefore, other 
approaches to target HER2/neu over-expressing tumor cells would be of great value.  
Our approach to targeting HER2/neu positive tumor cells is to use the same 
mechanism that the immune system uses to target and kill tumors, that is to target 
peptides derived from the HER2/neu protein when bound and presented by the 
Major Histocompatibility Complex (MHC).  The interaction of the T cell receptor 
(TCR) with peptide/MHC complex is the fundamental event that triggers the adaptive 
immune response [12].  T cells identify tumor cells by recognizing peptides derived 
from tumor-associated molecules.  The TCR would theoretically be an excellent 
probe to use for tumors, except that the TCR is frequently not amenable to 
manipulation and recombinant expression and its affinity for particular pMHC is 
relatively poor (the dissociation constant in the high µM range) [13-19].  Monoclonal 
antibodies would be a much better approach, because they are robust molecules 
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and their production is well established.  Antibodies that target specific pMHC on the 
surface of tumor cells have been produced but for some unknown reason, producing 
them conventionally is very difficult.  When available, these TCR-like antibody 
fragments appear to bind similarly to TCR binding pMHC [20,21]. Antibodies (or 
antibody fragments) previously isolated from phage-display libraries exhibited 
relatively low affinity for the pMHC complexes [22-24].  
In this study, we isolated a T-cell receptor like Fab that specifically targets the 
HER2/neu peptide, E75 (KIFGSLAFL), bound to the human MHC, Human Leukocyte 
Antigen, HLA-A2 from a synthetic antibody library using phage display.  The Fab 
binds with nanomolar binding affinity and high specificity for the E75/HLA-A2 pMHC 
molecule.  The Fab was then modified to attach radioactive 64Cu and used for in vivo 
PET/CT imaging experiments on tumor-bearing mice that express HLA-A2 
transgenically.  The Fab showed increased retention in the HER2/neu pMHC 
positive tumors compared to HER2/neu pMHC negative tumors.   These TCR-like 
antibodies can be used to study antigens presented on diseased and antigen-
presenting cells and for delivering therapies in tumor and T-cell based diseases.   
2.2 Materials and methods   	  
Ethics statement. This study was completed in strict accordance with the 
Association for Assessment and Accreditation of Laboratory Animal Care at the 
University of North Carolina (UNC) Animal Facility and the mice were handled 
according to the UNC Office of Animal Care and Use.  All experimentation was in 
accordance with the protocol (08-235.0) approved by the UNC Institutional Animal 
Care and Use Committee.   
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Cells and culture conditions.  MDA-MB-231, MCF7, and LNCAP tumor cells, CHO 
cells, T2 lymphoblast cells were purchased from ATCC.  SKOV3 and SKOV3 cells 
transfected with HLA-A2 were a generous gift from Dr. Jonathan Serody 
(Department of Microbiology, UNC – Chapel Hill, NC) [25].  Unless otherwise 
mentioned all media supplies were purchased from Mediatec, Inc. (Manassas, VA).  
Each of the cell lines were grown in RMPI 1640 supplemented with 10% heat-
inactivated FBS (Atlanta Biologicals, Inc.; Lawrenceville, GA), 10 mM sodium 
pyruvate, and penicillin/streptomyocin in humidified CO2  (5%) incubator at 37 °C.  
SKOV3 transfected HLA-A2 cells and CHO transfected HLA-A2 cells were grown in 
the same conditions as above with the addition of 2.5 mg/ml G418.     
Antibodies and synthetic peptides.  Anti-c-erb B-2 Ab-2 (9G6.10) was purchased 
from NeoMarkers (Fremont, Ca).  Alexa Fluor 647 labeled Goat anti-mouse IgG1, 
PE labeled mouse IgG2b, and Alexa Fluor 647 labeled Streptavidin were purchased 
from Invitrogen, Inc.  PE labeled mouse anti-Human HLA-A2 clone BB7.2 was 
purchased from BD Biosciences.  The peptides: E75 (from HER2/neu; KIFGSLAFL, 
residues 369-377); ML (from calreticulin; MLLSVPLLL, residues 1-9); YM (from 
human papillomavirus 16 (HPV-16) E7 oncoprotein; YMLDLQPETT, residues 11-
20); RL (from HER2/neu; RLLQETELV, residues 689-697); HY (from HER2/neu; 
HLYQGCQVV, residues 48-56); KT (from gp100 glycoprotein; KTWGQYWQV, 
residues 154-162); IL (from HIV-1 RT ILKEPVHGV; residues 476-484); and HA 
(from influenza hemagglutinin; IYSTVASSL, residues 518-526) were synthesized by 
the UNC Peptide Synthesis Facility (Chapel Hill, NC).   
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Generation of peptide bound HLA-A2 complexes.  The human MHC, HLA-A2.1, 
human beta-2-microglobulin (β2M), mouse beta-2-microglobulin, and murine H-2 Kd 
were produced as inclusion bodies in E. coli BL21 (DE3) (Invitrogen, Inc.).  Protein 
was folded in vitro as described previously [26].  Briefly, peptide, β2M, and HLA-A2 
heavy chain in a 10:1:1 molar ratio were injected into a folding buffer consisting of 
100 mM Tris pH 8.0, 400 mM arginine, 2 mM EDTA, 5 mM glutathione (reduced), 
0.5 mM glutathione (oxidized), and protease inhibitors PMSF, pepstatin and 
leupeptin.  The total final protein concentration was never greater than 50 µg/ml.  
After incubation for 24-36 hours at 10 °C the folded pMHC was concentrated in an 
Amicon ultrafiltration cell (Millipore, Billerica, MA) and purified using gel filtration 
chromatography (Phenomenex, Inc.; Torrance, CA).  The purified pMHC molecules 
were concentrated to greater than 3 mg/ml and stored at -80°C until use. Typical 
yield for each 1 L refold is about 5 mg of pMHC, which is approximately a 14% yield.  
The pMHC was site specifically biotinylated with the biotin ligase BirA (Avidity, LLC; 
Aurora, Colorado) according to the manufacturer’s instructions.  A non-denaturing 
SDS PAGE gel shift assay (no reducing agent, no heat treatment) was used to 
confirm that the pMHCs were biotinylated. 
Construction of Fab library.  We first constructed a template plasmid for 
constructing libraries, pFab007. This plasmid contains a modified version of the Fab-
4D5 gene [27] fused to gene III of the M13 phage (corresponding to the carboxyl-
terminal 208 residues of pIII). This fusion protein contains the cysteine residue of the 
heavy chain hinge region so as to enable bivalent display of the Fab [28].  Most 
residues in the CDR-L3, H1, and H2 loops were replaced with serine.  A TAA stop 
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codon and a unique BamHI site were introduced to CDR-H3.  The gene was 
assembled from a series of synthetic oligonucleotides using PCR.  The synthesized 
gene and the phoA promotor segment were cloned into a phage-display vector, 
pAS38 [29] in such a way that the heavy chain of the Fab is fused to the carboxyl-
terminal 208 residue segment of M13 phage pIII.  The expression of both the light 
chain and the heavy chain-p3 fusion were placed under the control of the phoA 
promotor. 
 The library was constructed as follows.  Oligonucleotides that encode biased 
amino acid mixture (indicated as “X”s in Figure 1B) for CDR-L3 and H3 were 
synthesized using a custom-made trimer phosphoramidite mixture (Glen Research, 
Sterling, VA) on an Expedite synthesizer (ABI) following instructions from Glen 
Research. After deprotection, the oligonucleotides were purified using acrylamide 
gel electrophoresis. Oligonucleotides for CDR-H1 and H2 that did not require the 
use of trimer phosphoramidetes were purchased from Integrated DNA Technologies.  
These oligonucleotides were used to introduce mutations of CDR-L3, CDR-H1, 
CDR-H2 and CDR-H3 using the Kunkel mutagenesis method [30]. After the initial 
transformation of the SS320 cells [30], the DNA for the library was purified and 
digested with BamHI and then used to transform the SS320 cells and produce 
phage particles, as described [27].  In this manner clones harboring non-mutated 
CDR-H3 were eliminated. This Fab library, “Library E,” contained approximately 1010 
independent clones.  
Selection of phage-displayed antibody fragments.  The library sorting was 
performed as previously described [27] with minor modifications.  From the second 
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round on, enriched phages were first incubated with streptavidin-coated magnetic 
beads, and phages that bound to the beads were removed.  The “precleared” 
phages were then incubated with biotinylated pMHCs in solution and then captured 
with the streptavidin-coated magnetic beads. The pMHC concentrations used were 
100, 50, 10 and 10 nM for the first, second, third and fourth rounds, respectively. 
Phages captured on the beads were eluted in 100 µl of 0.1M Gly-HCl (pH 2.1) buffer 
and immediately neutralized with 35 µl of 1M Tris-Cl buffer (pH 8). Recovered clones 
were analyzed using phage ELISA and DNA sequencing as described previously 
[27]. 
Expression and purification of soluble recombinant Fabs.  The phage-display 
vectors for the isolated clones were converted into Fab expression vectors by 
inserting a gene segment encoding an 8x histidine tag and a termination codon at 
the 3’ end of the heavy chain gene.  The carboxyl terminus of the light chain 
encoded a substrate tag for the biotin ligase BirA (AviTag, Avidity, LLC.).  Fab 
proteins were expressed in the 55244 E. coli strain (ATCC) and purified using 
protein A affinity chromatography followed by cation exchange chromatography as 
described previously [27].  Approximately 2-5 mg of purified Fab were routinely 
obtained from 1 L bacterial culture.  SDS-PAGE analysis showed that Fabs were in 
>90% purity.     
Surface plasmon resonance experiments.  Approximately three hundred 
response units (RUs) of each antibody fragment were bound to respective flow 
channels in a Biacore Ni-NTA sensor chip (GE Healthcare) using the 8x histidine tag 
on the antibody fragments.  Soluble class I MHC (analyte) at concentrations ranging 
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from 200 nM to 1 nM in two fold dilutions was injected onto the surface at a flow rate 
of 20 µl/min in a 60-s pulse.  The NTA surface was regenerated using 0.2 M EDTA 
to remove all bound protein and then recharged with 0.04 M NiSO4.  The procedure 
was repeated until at least three curves were obtained for each concentration of 
analyte.  Curves obtained at each concentration were double referenced by first, 
subtracting the signal from the reference surface that contained no Fab from the 
signal for the reaction surface followed by subtraction of the average signal obtained 
from a set of buffer injections [31].  Data were processed using Scrubber (BioLogic 
Software, Campbell, Australia). The suitability of the fit was measured based on the 
appearance of residuals and χ2 values.  For each Fab-pMHC binding curve, the 
predicted curves visually overlaid well with the experimental curves.  The residuals 
also were small and random and χ2 was below 1. 
Production of Fab tetramers.  Purified Fabs were biotinylated using a site-specific 
biotin-ligase BirA (Avidity, LLC; Aurora, Colorado) according to the manufacturer’s 
instructions.  As described above for the biotinylation of pMHC, successful 
biotinylation of the Fabs was confirmed by gel shift analysis.  Biotinylated Fabs were 
incubated with streptavidin-alexa 647 (Invitrogen, Inc.) at a 4 to 1 molar ratio for ten 
minutes at room temperature to make the Fab tetramers.   
Flow cytometric analysis of peptide-loaded HLA-A2 on cell surface.  T2 cells 
are deficient in the TAP1 and TAP2 proteins that are responsible for transporting 
antigenic peptides from the cytoplasm to the endoplasmic reticulum, but are able to 
be loaded with exogenous peptides for loading of HLA-A2 molecules on their cell 
surface.  T2 cells (1 x 106/ml) were incubated in RPMI medium and incubated with 
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one of the peptides E75, ML, IL, YM, RL, HL, KT, or IL (50 mM) overnight.  After the 
incubation, the cells were washed to remove the excess peptide and incubated with 
either BB7.2 Ab (0.5 mg/ml) to detect the level of HLA-A2 molecules present on the 
surface or the complex of biotinylated fE75 or fML1 with streptavidin-alexa 647 
(Invitrogen, Inc.) for 30 min. at 4°C.  Incubating the T2 cells with peptides leads to an 
observable increase in BB7.2 staining compared with untreated cells.  In all 
experiments, the IgG2b isotype control was included for determining nonspecific 
binding. Flow cytometry data were analyzed using Summit software (Beckman 
Coulter, Inc.).  
Tumor cell staining.  All adherent tumor cell lines were detached from the tissue 
culture flask using 1 x trypsin/EDTA (Sigma-Aldrich, LLC).  Cells were washed and 
then incubated with anti-HER2/neu antibody (Anti-c-erb B-2 Ab-2, 9G6.10) for 30 
min. at 4°C followed by incubation with Alexa Fluor 647 labeled Goat anti-mouse 
IgG1 and PE labeled HLA-A2 clone BB7.2 to analyze the phenotype of each tumor 
cell line.  Separately, each tumor cell line was prepared as before, but stained with 
Fab-Alexa Fluor 647-streptavidin tetramer for 30 min. at 4°C.  After the final staining 
incubation, cells were washed and analyzed by flow cytometry (Cyan, Beckman 
Coulter, Inc.). Pearson's correlation coefficient and multiple linear regression 
analysis were completed for the mean and median fluorescence intensity observed 
for each cell line’s HLA-A2, Her2/neu, and Fab staining.  No difference was 
observed whether mean or median fluorescence was used for the analysis. 
DOTA conjugation and 64Cu radiolabeling.  All solvents were prepared from 
18MΩ water and eluted from a column of chelex 100 (Serological Research Institute) 
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to remove metals from all buffers.  Free metals were removed from purified Fabs by 
dialysis twice with 1L of 0.2 M NaHCO3 at pH 8.2.  Fabs were conjugated to S-2-(4-
Isothiocyanatobenzyl-)1,4,7,10-tetraazacyclo-dodecane-tetraacetic acid (DOTA-
NCS) purchased from Macrocyclics (Dalax, TX) by using the isothiocyanate linkage 
method as described previously [32].   The molar ratio of the DOTA conjugate to Fab 
used was 5:1.  The reaction proceeded at pH 8.2 in 0.2 M NaHCO3 over 18 hours at 
room temperature.  Unconjugated DOTA was removed from the reaction by a PD-10 
desalting column (GE Healthcare).  The average number of chelates per Fab was 
determined as described previously [33].  The positron emitting isotope 64Cu (copper 
chloride in 0.1 mol/L HCl; radionuclide purity, >99%) was provided by Mallinckrodt 
Institute of Radiology (Washington University School of Medicine, St. Louis, WA).  
The DOTA-conjugated Fab (20 µM) was incubated with approximately 1.5 mCi of 
64CuCl2 in 1.0 mM citric acid (pH 5.5).  The solution was incubated for 1 hr at 40 °C.  
The reaction was monitored by TLC (silica) and developed with 0.1 M ammonium 
acetate (25%)/0.001 M citric acid (25%) / methanol (50%).  Free 64Cu was 
complexed as 64Cu citrate with an Rf>0.5 and 64Cu DOTA-Fab had an Rf<0.5.  The 
radiochemical yield was determined to be > 97.0%.   
Cell binding assay of radiolabeled fE75 Fab.  The SKOV3 cells transfected with 
HLA-A2 were harvested as previously described for tumor cell staining.  The cells 
were incubated with the purified 64Cu DOTA-Fab at increasing concentrations for 30 
min. at 4°C.  As a demonstration of specificity, the SKOV3 transfected HLA-A2 cell 
line was incubated with 64Cu DOTA-Fab at increasing concentrations and 300 nM 
soluble E75/HLA-A2 pMHC.  Following the incubation, the cells were washed twice 
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and then the bound radiolabeled fE75 counts per minute (cpm) was measured with a 
2470 WIZARD2 automatic gamma counter (PerkinElmer Inc.). 
Micro Positron Emission Tomography/Computed Tomography (microPET-CT) 
imaging in tumor-bearing mice. The preliminary experiments used NOD.SCID 
(SCID) mice with single tumors injected subcutaneously into the flank of the mouse.  
SCID and HLA-A2 transgenic NOD.SCID mice were a gift from Dr. Jeffrey Frelinger 
(Department of Immunobiology, University of Arizona) [34].  All SCID mice were 
injected subcutaneously on either the right or left flank with either negative control 
tumors 1 x 106 SKOV3 (4 mice) or positive tumors SKOV3 transfected HLA-A2 cells 
(3 mice).  Following these experiments, we used HLA-A2 transgenic SCID mice and 
because of limitations in the number of available mice, injected both tumors on 
opposite flanks of each mouse.  The HLA-A2 transgenic SCID mice were injected 
with 1 x 106 MDA-MB-231 cells and SKOV3 cells on opposite flanks (3 mice).  Mice 
were monitored every other day by palpation and the size of tumor growth was 
measured.  Once the tumor growth could be observed by palpation, mice were 
injected with the Fab and imaged using a microPET-CT (eXplore Vista PET-CT, GE 
HealthCare, Inc.).  Mice were injected with approximately 20 µg of 64Cu-DOTA-Fab 
(specific activity: 50-60 µCi/µg) in PBS via the tail vein.  For all scans, mice were 
anesthetized using 2% isoflurane, positioned in a prone position along the long axis 
of the microPET scanner and imaged.  Dynamic PET acquisitions were taken over 
the first hour for selected mice.  Static acquisitions were taken for 10 min. at one-
hour post injection for all mice.  All mice were additionally imaged by micro 
computed tomography (microCT) prior to the microPET scan in the same 
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bedposition for anatomical reference.  Following the imaging, tumors were excised, 
cryopreserved with liquid nitrogen, and cryosectioned for radiographic analysis.  PET 
images were reconstructed using an ordered subsets-expectation maximization 
(OSEM) algorithm with scatter, random, and attenuation corrections, and the PET 
pixel size was 0.3875 x 0.3875 x 0.775 mm [35].  Standardized uptake values 
(SUVs) were calculated pixel-wise by normalizing for injected dose and animal 
mass.  The PET images were coregistered with the microCT images using the 
scanner software for identification of anatomical structures.  Reconstructed 
microPET and microCT images were viewed and regions of interest (ROIs) drawn 
and SUVs quantified using AMIDE [36].  Tumor ROIs were drawn manually to avoid 
adjacent organs and tumor metastases because the metastases typically had very 
poorly defined borders.  Average SUV was measured for each specified ROI.  The 
student’s t test was used to compare the SUVs from single tumor bearing SCID 
mice.  The paired student’s t test was used to compare the SUVs from the tumors of 
the double tumor-bearing, HLA-A2-transgenic SCID mice. 
2.3  Results  	  
Generation of synthetic antibody-fragments specific to pMHC complexes.  
Our goal is to develop tools to target specific tumor cells in vivo for diagnostic testing 
and treatment.  We hypothesized that peptides bound to MHC would be good 
targets for such tools.  The HER2/neu peptide E75 (KIFGSLAFL) was selected for 
analysis based on its clinical relevance to HER2/neu over-expression [37-39] and 
the success of E75 peptide vaccines and targeting using E75 in peptide-pulsed 
dendritic cell immunization therapies [40,41].  It has been notoriously difficult to 
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create monoclonal antibodies (mAb) to specific peptide/MHC complexes, 
presumably because of the sequence conservation between MHC molecules 
injected and present in the immunized mouse [42].   
As an alternative to conventional mAb production, we sought to isolate 
antibody-fragments (Fabs) specific for peptide-bound MHC molecules using phage-
display technology.  We utilized a “synthetic” antibody library built on a highly stable 
4D5 Fab scaffold (Figure 1A) [43] in which the amino acid diversity in the 
Complementarity Determining Regions (CDR) was designed using simple but highly 
tailored amino acid mixtures [27].  Because such synthetic antibody libraries are not 
subjected to clonal selection against self-antigens, unlike common recombinant 
antibodies derived from natural immune systems, we felt that synthetic antibody 
libraries, coupled with phage-display selection, offered a particularly effective 
approach to generating antibodies to pMHCs.  Based on our previous work [27], we 
constructed a new antibody library in which four of the six CDRs were diversified, as 
described in Figure 1B.  This library is similar to “Library D” of Fellouse et al. [27], 
but its amino acid diversity in CDR-L3 was expanded and also the composition of 
the expanded amino acid diversity, designated as X in Figure 1, was modified based 
on the analysis of antibody clones isolated from Library D [27]. 
We used the HER2/neu derived peptide, E75 (KIFGSLAFL), or calreticulin 
derived peptide, ML (MLSVPLLL), bound to the human MHC molecule HLA-A2 as 
the targets for sorting the synthetic antibody library. After four rounds of selection, an 
ELISA was used to test for specificity of the amplified phage Figure 1C.  We 
identified three distinct classes of antibodies:  (i) selective to E75/HLA-A2, (ii)  
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Figure 1: Phage-Display isolation of Fabs specific for pMHC molecules. Fabs 
specific for either E75/HLA-A2 or ML/HLA-A2 molecules were selected by phage-
display technology.  Each Fab construct was built from the highly stable 4D5 Fab 
scaffold containing both a heavy and light chain each with a single variable and 
constant domain (modeled from PDB ID: 1FVD) (A). The diversity of the 
Complementary Determining Regions (CDR) for the heavy chain; H1, H2, and H3, 
and the light chain; L3, was restricted in favor of tyrosine, serine, and other small 
amino acids.  The Cα atoms of the synthetically modified H1, H2, H3, and L3 regions 
are shown as spheres (B).  After three rounds of selection, an ELISA was used to 
test the specificity of the amplified clones (C).  Three clones with three different 
specificities were identified.  The Fab clones fE75 and fML bound E75/HLA-A2 and 
ML/HLA-A2 respectively with no detectable binding to the opposite pMHC molecule.  
The Fab clone fE2 showed binding to both E75/HLA-A2 and ML-HLA-A2.  Following 
each Fab clone’s specificity determination, the amino acid sequence of each clone 
was determined (D).  
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selective to ML/HLA-A2, and (iii) cross-reactive to the two pMHCs.  Two clones, 
fE75 and fML, selective to E75/HLA-A2 and ML/HLA-A2 respectively, were chosen 
for further study based on the phage ELISA, which identified each phage clone to 
have high affinity and specificity for their respective pMHC.  As expected, the two 
clones have distinct CDR sequences (Figure 1D). 
To assess the binding affinity, kinetics and specificity of the two Fabs, they 
were produced as soluble proteins, with a His-tag at the C-terminus of the heavy 
chain and a biotinylation tag at the C-terminus of the light chain and characterized 
using Surface Plasmon Resonance. The results shown in Figure 2 demonstrate that 
the model appropriately describes the binding responses of each Fab for its cognate 
pMHC molecule, with curve fitting residuals at or below 1 RU.  The KD value for fE75 
binding E75/HLA-A2 was determined to be 59 +/- 4 nM based on three separate 
experiments (Figure 2A).  The KD for fML binding ML/HLA-A2 was 79 +/- 4 nM based 
on three separate experiments (Figure 2D).  No binding was observed for fE75 and 
fML binding the non-cognate pMHC (Figure 2B, 2C), or to other non-cognate pMHC 
molecules that differed in peptide alone or unrelated peptide bound to unrelated 
MHC (data not shown).  
Fabs bind to cell surface pMHC.  In order to test whether these Fabs can be 
used to find specific pMHC on the cell surface, Fab-displaying streptavidin tetramers 
were made and used to bind to peptide pulsed T2 cells.  The T2 cell line is deficient 
in pMHC cell surface expression due to the absence of the transporter associated 
with antigen processing (TAP1 and TAP2).  The MHC HLA-A2 on the surface of T2 
cells is more “peptide-receptive” than on normal cells and therefore; specific  
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Figure 2.  TCR-like Fabs Bind Cognate pMHC with Nanomolar Affinity.  SPR 
binding response curves of fE75 binding E75/HLA-A2 (A) and ML/HLA-A2 (B) and 
fML binding E75/HLA-A2 (C) and ML/HLA-A2 (D) are shown.  Each Fab was 
immobilized onto individual flow channels in an NTA-Ni chip.  Kinetic data for each 
Fab binding each pMHC molecule were globally fit to a bimolecular reaction.  Green 
and blue lines designate the start and end respectively of each pMHC injection.  
Binding curves and curve fits are drawn in black and orange respectively.  Each 
binding curve represents a different concentration of pMHC beginning at 200 nM and 
decreasing to 1.5 nM in 2 fold dilutions. No binding was observed for either Fab 
binding non-cognate pMHC molecules up to 400 nM.   
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peptides may be loaded onto HLA-A2 by incubating these cells with exogenous 
peptides [44].  T2 cells were incubated with ML, E75 or control peptides.  The 
biotinylated Fabs were respectively conjugated to fluorescently-labeled streptavidin 
to form “Fab tetramers”.  The fE75 tetramer bound to T2 cells incubated with E75 
(Figure 3A), but not to untreated cells.  Similarly, the fML tetramer bound to T2 cells 
incubated with ML (Figure 3B), but not to untreated cells.  Additionally, neither Fab 
bound to T2 cells incubated with any of the control peptides (Figure 3C).  Therefore, 
in agreement with the SPR experiments, these Fabs bound specifically to their 
cognate pMHC expressed on the cell surface. 
The Fabs detect endogenously processed and presented pMHC complexes.   
Addition of exogenous peptide to T2 cells generates a much higher density of the 
particular peptide/MHC molecule on the cell surface compared with endogenous 
levels found on normal TAP expressing cell types [45,46].  Thus, we evaluated the 
ability of fE75 and fML to recognize physiological levels of peptide presented by the 
HLA-A2 molecule using flow cytometric analysis of several human tumor cell lines: 
MDA-MB-231 breast tumor cells (HLA-A2pos and HER2/neupos); SKOV3 HLA-A2 
transfected ovarian tumor cells (HLA-A2pos and HER2/neupos); MCF7 breast tumor 
cells (HLA-A2pos and HER2/neupos); LNCaP prostate tumor cells (HLA-A2pos and 
HER2/neupos); and negative control SKOV3 ovarian tumor cells (HLA-A2neg and 
HER2/neupos).  All the cell lines express HER2/neu at varying levels.  Thus, as 
anticipated, the HLA-A2 positive human cell lines showed variable fE75 binding 
compared to the negative control tumor cell line SKOV3 (HLA-A2neg) as shown in 
Figure 3D.  All of the HLA-A2 positive cell lines had similar binding of the fML Fab 
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(Figure 3E), but comparable to fE75, neither Fab bound to the HLA-A2 negative 
control cell line SKOV3 (Figure 3F).  In addition, a further control was added with a 
CHO cell line transfected with HLA-A2.  This cell line was HLA-A2 positive but 
HER2/neu negative.  No binding of either fE75 or fML1 was observed for this cell 
line (data not shown).     
Next, we sought to understand the cause for the differences in fE75 binding to 
the tumor cell lines in order to improve our ability to use the TCR-like Fabs as 
diagnostic and treatment tools.  The cell surface level of peptide/HLA-A2 complexes 
is dependent on multiple parameters including: protein antigen availability, peptide 
generation by the proteasome, antigen processing, and MHC expression [47].  The 
data allow us to determine which protein plays a more important role in the level of 
any particular pMHC complex at the cell surface: MHC (HLA-A2) or antigen 
(HER2/neu).  We measured HER2/neu and HLA-A2 expression by flow cytometry.  
There were significant differences in both HLA-A2 expression and HER2/neu levels 
between the cell lines (Figure 4A-F).  The MDA-MB-231 cell line had the highest 
level of HLA-A2 expression, but also the lowest HER2/neu levels.  Both MCF7 and 
LNCaP cell lines had intermediate levels of HER2/neu, but lower expression of HLA-
A2.  The SKOV3 HLA-A2 cell line had the highest level of HER2/neu and the second 
highest MFI of HLA-A2.   
Simple two-dimensional linear regression analysis models showed weak 
correlation of fE75 MFI with HLA-A2 (r2=0.40) and weak, but stronger correlation 
with HER2/neu expression (r2=0.62) (Figure 4 G-H).  Both of the regression 
analyses were dominated by the contribution made by MDA-MB-231.  If that cell line  
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Figure 3. Fabs bind specifically to endogenously processed and presented 
levels of pMHC molecules.  Flow cytometric analysis revealed that the Fab 
tetramer, composed of biotinylated fE75 (A) or fML (B) and streptavidin-Alexa-647, 
bound to T2 cells incubated with the cognate peptide, but not to control peptides or 
untreated T2 cells in three separate experiments.  In C, a graph of the MFI for 
several other control peptides against the cognate peptide for each Fab was shown.  
The staining of HER2/neu positive tumor cell lines by the fE75 and fML tetramers 
was shown in D and E respectively.  The graph of the MFI for one representative 
experiment from four total was shown in F. 
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Figure 4. HLA-A2 and HER2/neu expression is high variable on each tumor cell 
line.  The surface expression of HLA-A2 and HER2/neu for each human tumor cell 
line was measured by flow cytometry.  The representative plots of HLA-A2 versus 
HER2/neu for each tumor cell line were shown in A-E.  In F, a graph of the MFI of 
one representative experiment from four total was shown. G and H were plots of the 
MFI of fE75 versus the MFI of HLA-A2 or MFI of HER2/neu respectively.  Simple 
two-dimensional linear regression analysis models do not model the system well.  
The black lines showed weak correlation of fE75 MFI with HLA-A2 (r2=0.40) or 
HER2/neu expression (r2=0.62). 
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were removed from the analysis, no correlation exists for fE75 MFI and HLA-A2 
(r2=0.09) nor HER2/neu (r2=0.00).  Since that is not meaningful biologically and we 
know that fE75 binding did vary for each cell line, we know that either there was 
another unknown important factor or that both HLA-A2 and HER2/neu influenced 
fE75 binding. The coordinated involvement of both HLA-A2 and HER2/neu on fE75 
levels was modeled using multi-parameter linear regression analysis [48].  This 
model gave an excellent fit for the correlation of fE75 binding using both HLA-A2 and 
HER2/neu expression levels (r2=0.97).  Removing the MDA-MB-231 cell line from 
this analysis showed that there was still a significant correlation (r2=0.89), 
suggesting that even though MDA-MB-231 appears to dominate the regression, the 
correlation between fE75 binding and both HLA-A2 and HER2/neu is valid even 
without the MDA-MB-231 cell line.  These data show that both MHC expression 
levels and the antigen expression affect pMHC expression on tumor cell lines.  Both 
MHC and source of the peptide antigen must be considered in order to accurately 
predict pMHC expression levels. 
The TCR-like Fab recognizes E75/HLA-A2 positive tumors in a 
xenotransplanted-tumor mouse model. To address whether the TCR-like Fabs can 
be used in vivo, we used positron emission tomography-computed tomography 
(PET-CT), which provides excellent sensitivity to radiolabels, allowing quantification 
of the uptake of the imaging agent at the tumor [49].  The Fab, fE75, was made into 
a PET imaging agent by attaching a chelator, S-2-(4-Isothiocyanatobenzyl)-1,4,7,10-
tetraazacyclo-dodecane-tetraacetic acid (DOTA-NCS).  The DOTA chelator provides 
flexibility as it can chelate both 64Cu for PET and 111In for single-photon emission 
	   	  41	  
computed tomography (SPECT).  We routinely obtained an average of 0.7 moles of 
DOTA per mole of fE75.  The yield of 64Cu- fE75-DOTA conjugate was obtained in 
greater than 95% purity as determined by thin layer chromatography.  To confirm 
that addition of this chelator and the radioactive metal did not alter the binding 
affinity of fE75 for E75/HLA-A2, in vitro cell binding studies were performed.  The 
ovarian tumor cell line SKOV3 transfected with HLA-A2 was incubated with a range 
of concentrations of radiolabeled Fab.  A Scatchard analysis was used to calculate a 
binding affinity of 111 nM (95% CI:  63-159), which was in good agreement with the 
SPR data (59 +/- 4 nM).  The 64Cu- DOTA-fE75- conjugate maintained its specificity 
for E75/HLA-A2, as soluble recombinant E75/HLA-A2 complexes were able to block 
binding of the radio-labeled fE75 to SKOV3/HLA-A2 cells (Figure S1).   
The first test of uptake of the labeled fE75 used severe combined 
immunodeficiency (SCID) mice.  These mice do not express either human 
HER2/neu or HLA-A2.  The question asked is whether once the Fab is injected into 
the tail vein, will it be able to accumulate in the tumor.  The 64Cu- DOTA-fE75 
conjugate was injected via the tail vein of SCID mice bearing either 
xenotransplanted SKOV3 or SKOV3 HLA-A2 tumors.  MicroPET (color) and 
microCT (black and white) images of the mice were collected and overlayed (Figure 
5A and5B). The xenografted human tumors on either the left or right flanks were 
clearly identifiable in all microPET/CT images.  The relatively small size of the Fab 
(~55 kDa) was below the renal clearance threshold of approximately 64 kDa 
meaning that it should be rapidly eliminated by renal clearance [50-55].  Literature 
indicated that the large signal from the liver might be attributed to Cu/Zn superoxide 
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dismutase (SOD1), chelation of the 64Cu [56,57].  Tumors have been shown to trap 
injected materials non-specifically [58], but, there was very little uptake of 64Cu-
DOTA-fE75 in the HLA-A2 negative SKOV3 control tumor (Figure 5A,C; labeled ct) 
suggesting that this is not a significant problem in our model.  In contrast, there was 
easily observable uptake of the fE75 imaging agent in the HLA-A2 positive tumor 
(Figure 5B,D; labeled pt).  Even after one hour, increased up-take at the HLA-A2 
positive tumor sites was observed, but not at the negative control tumor.  
Accumulation of 64Cu-DOTA-fE75 was observed at the edges of the tumor that 
suggested at first that the Fab did not penetrate the tumor well.  However, visual 
inspection of the sectioned tumor showed necrosis in the center of the tumor and 
radiography of the tumors (Figure S2) showed that the Fab was bound appropriately 
on the outside where live tissue remains.  PET/CT images of additional human 
tumor bearing SCID mice were shown in Figure S3.  These data showed that the 
Fab does accumulate at the site of the correct tumor.  
Dynamic scans over the course of sixty minutes (Figure 5E and 5F), show 
that there is an initial rapid accumulation of 64Cu- DOTA-fE75 followed by a steady-
state in all the tissues (liver, kidney, humoral muscle, and control tumor) except for 
the HLA-A2 positive tumor.  The HLA-A2 positive tumors showed initial rapid 
accumulation followed by a steady rise in the 64Cu- fE75-DOTA signal suggesting 
that specific binding occurs.  The ratio of the slope of the Standard Uptake Values 
(SUVs) from 300 to 3600 sec. for the HLA-A2 positive tumors compared to the HLA-
A2 negative control tumors was 6.6.  This was expected if 64Cu-DOTA-fE75 were to 
accumulate due to binding to its cognate pMHC, E75/HLA-A2, at the HLA-A2 
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positive tumors.  Furthermore, an unpaired t test analysis of the SUVs of the 64Cu-
DOTA-fE75 signal sixty minutes post injection gave a statistically significant 
difference between the HLA-A2 positive tumors and the HLA-A2 negative tumors (p 
< 0.004, n=4).  Together these experiments demonstrate that the fE75 Fab can 
accumulate in tumors that present E75/HLA-A2 on their cell surface in vivo. 
While the experiments above show that 64Cu-DOTA-fE75 can target a pMHC 
in vivo, they do not mimic an important consideration for human use.  In humans, 
most cells in the body express HLA-A2 bound numerous different peptides found in 
each cell type [59,60].  If the 64Cu-DOTA-fE75 imaging agent has a small degree of 
non-specific binding to HLA-A2 with other peptides, we would not see accumulation 
at the tumor because the Fab would be greatly diluted by the nonspecific binding 
before arriving at the tumor.  Thus, we used an HLA-A2 transgenic mouse crossed 
to the SCID background, which allows for the tumors to grow and for all of the 
mouse cells to express HLA-A2.  The HLA-A2 transgenic SCID mice were 
xenografted with the SKOV3 (control tumor, ct) and MDA-MB-231 (positive tumor, 
pt) (Figure 6A,B and Figure S3C).  Dynamic scans were obtained over sixty minutes 
following tail-vein injection of 64Cu-DOTA-fE75 (Figure 6C).  The dynamic curves 
from the HLA-A2 transgenic SCID mice were similar to what was seen in the SCID 
mice that did not express HLA-A2 (Figure 5E-F).  The ratio of the calculated slopes 
of the SUVs from 300-3600s for the HLA-A2 positive tumor compared to the HLA-A2 
negative control tumor was 3.8, again indicating positive accumulation of 64Cu-
DOTA-fE75 at the HLA-A2 positive tumor.  Furthermore, comparison of the SUVs 
sixty minutes post injection showed that the human tumors positive for HLA-A2 and 
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Figure 5. TCR-like Fab binds specifically to human tumor cells in SCID mice.  
Mice were injected intravenously with 64Cu-DOTA-fE75, which binds to tumors 
expressing both HLA-A2 and HER2/neu in vivo.  Coronal views of small-animal PET 
images with coregistered CT images of SCID mice bearing human tumor (SKOV3 or 
SKOV3 HLA-A2) xenografts (A and B) in flanks at 1 h post-injection. Intensities of 
PET slices were scaled to the same maximum.  Cropped views of only the tumors 
designated by the white boxes for the mice presented in A and B were shown in C 
and D respectively.  The standardized uptake values (SUV) for 64Cu-DOTA-fE75 in 
the tumors and selected organs over time were shown below each respective mouse 
(E and F).  B = bladder, h = humeral muscle, k = kidneys, l = liver, ct = control HLA-
A2 negative tumor; SKOV3 cell line, pt = HLA-A2 positive tumor; SKOV3 HLA-A2.     
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Figure 6. TCR-like Fab binds specifically to human tumor cells in HLA-A2 
transgenic SCID mice.  Similarly as describe for the SCID mice experiments 
(Figure 5), HLA-A2 transgenic SCID mice were injected intravenously with 64Cu-
DOTA-fE75.  Coronal views of the small-animal PET image with coregistered CT 
images of a scid HLA-A2 transgenic mouse bearing human tumor (MDA-MB-231 
and SKOV3) xenographs (A) in flanks at 1 h post-injection. Intensities of PET slices 
were scaled to the same maximum.  Cropped views of only the tumors designated 
by the white boxes were shown in B respectively.  The standardized uptake values 
(SUV) for 64Cu-DOTA-fE75 in the tumors and selected organs over time were shown 
in C.  B = bladder, h = humeral muscle, k = kidneys, l = liver, ct = control HLA-A2 
negative tumor; SKOV3 cell line, pt = HLA-A2 positive tumor; MDA-MB-231 cell line.     
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Figure S1.  Saturation () binding curves of 64Cu-DOTA-fE75 and SKOV3 HLA-
A2 (E75/HLA-A2 pMHC positive) cells.  Each data point represents the mean ± 
standard error of the mean of triplicate measurements.  The KD of 64Cu-DOTA-fE75 
was determined to be 111 nM (95% CIs:  63-159). 64Cu-DOTA-fE75 binding (Ο) to 
SKOV3 HLA-A2 cells blocked by 300 nM soluble E75/HLA-A2 pMHC.  
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Figure S2.  Radiography images of excised human tumors from 64Cu-DOTA-
fE75 injected SCID and HLA-A2 transgenic SCID mice.  HLA-A2 positive and 
HLA-A2 negative tumors from SCID mice were shown in A and B. HLA-A2 positive 
and HLA-A2 negative tumors from HLA-A2 transgenic SCID mice were shown in C-
F.     
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Figure S3.  Additional PET/CT images of SCID and HLA-A2 transgenic SCID 
mice.  Mice were injected intravenously with 64Cu-DOTA-fE75, which binds to 
tumors expressing both HLA-A2 and HER2/neu in vivo.  Coronal views of small-
animal PET images with coregistered CT images of SCID mice bearing human 
tumor (SKOV3 or SKOV3 HLA-A2) xenografts (A and B) or HLA-A2 transgenic SCID 
mouse bearing two tumors (SKOV3 and MDA-MB-231) xenografts (C) in flanks at 1 
h post-injection were shown. Intensities of PET slices were scaled to the same 
maximum.  Cropped views of only the tumors designated by the white boxes for the 
mice presented in A, B, and C were shown in D, E and F respectively.  B = bladder, 
h = humeral muscle, k = kidneys, l = liver, ct = control HLA-A2 negative tumor; 
SKOV3 cell line, pt = HLA-A2 positive tumor; SKOV3 HLA-A2 or MDA-MB-231.     
 
 
 
 
	  
	   	  49	  
HER2/neu had statistically significant uptake and retention of 64Cu-DOTA-fE75 
compared to the negative control tumor SKOV3 (paired t test, p < 0.03, n=4).  This is 
a significant achievement in specificity because the 64Cu- fE75-DOTA was exposed 
to millions of HLA-A2 molecules with various peptides and still accumulated at the 
HLA-A2 positive tumors.  
2.4  Discussion 	  
Our long-term goal is to construct a generalized approach to specifically 
target tumors in vivo for diagnostic and therapeutic use.  We have used imaging as 
our first goal because we rationalize that if we can image specifically, we can target 
therapeutics specifically. We began with the observation that the immune system is 
fully competent to target tumors in vivo [61-70].  A major portion of this response is 
composed of cytotoxic T cells.  T cells are able to recognize peptides derived from 
proteins in the cells, bound to MHC molecules (pMHC) using their clonotypic T cell 
receptor [71,72]. Unfortunately for the patient, the tumor infiltrating T cells do not 
always kill the tumors.  As a substitute for tumor specific recombinant T cell 
receptors, monoclonal antibodies that recognize specific pMHC complexes have 
been generated [24,45,46,73-80], but usually have low affinities compared to those 
isolated from bacteriophage libraries [78,81-83]. Rational design of high affinity 
antibodies directed towards pMHC has yielded affinities in the nanomolar range [84], 
but that approach is laborious and must be done for each antibody individually.  
The Fabs isolated from our synthetic antibody-fragment library have binding 
affinities in the mid-nM range, consistent with a previous work demonstrating the 
ability of these synthetic libraries to generate high-affinity antibodies without the 
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need for affinity maturation [27].  The level of affinity of our Fabs is approximately 
1000 times better than that for TCRs binding pMHC, which is typically in the µM 
range [85].  This is also roughly a 100-fold improvement over TCR-like monoclonal 
antibodies produced from classical hybridoma technology [86]. These Fab have 
affinities similar to other peptide/HLA-A2-specific antibodies isolated from 
bacteriophage libraries [87,88].  
Previous studies have suggested that the higher affinity of TCR-like Fab 
compared to T cell receptor is due to faster on-rates instead of slower off-rates [89].  
Our data are partially consistent with this concept as our Fabs bind cognate pMHC 
with faster rates of association, but our Fabs also show significantly slower rates of 
dissociation.  Therefore, increased affinity of TCR-like Fabs is not solely due to 
increased on-rates as has been suggested. 
Using these Fabs, we have shown that predicting pMHC levels on the cell 
surface is dependent highly on both MHC and HER2/neu antigen expression.  
Different tumor cell lines showed varying levels of fE75 binding/staining because 
they have highly different levels of HLA-A2 and HER2/neu.  In agreement with 
previous data [90], we observed no direct correlation between levels of E75/HLA-A2 
detected by fE75 and HER2/neu detected by mAb suggesting that HER2/neu levels 
are not directly correlated with E75/HLA-A2 levels on the cell’s surface.  However, 
multiple components are involved in the levels of any particular pMHC and often 
these components may affect one another.  Logically, it seems likely both HER2/neu 
and HLA-A2 levels would affect E75/HLA-A2 levels on the cell surface.  Multi-
parameter linear regression analysis yielded a strong correlation between fE75 
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binding and the both HLA-A2 and HER2/neu expression.  We conclude that both 
variables, the source protein and MHC levels, are both highly important.  
The fE75 Fab was demonstrated to bind selectively to HLA-A2 positive 
tumors in vivo in SCID mice.  Thus, fE75, a TCR-like Fab, can be used in vivo and 
potentially used as a drug delivery vehicle.  This is consistent with other reports that 
demonstrate that tumors xenografted in SCID mice were reduced or even eliminated 
as via complement fixation or induction of apoptosis [24,91].  Moreover, a TCR-like 
Fab fused to a truncated form of Pseudomonas exotoxin, PE38KDEL showed in vivo 
dose dependent xenografted tumor killing in SCID mice [87,92].  Immunotherapy 
and drug deliver by TCR-like Fabs is possible only if the specificity of the Fab is 
exceptional and does not bind to similar pMHC presented on healthy cell surfaces.   
However, our tests went one important step farther than those performed 
previously.  We showed that these TCR-like Fabs can function similarly to human T 
cells; they can be highly selective in vivo even in the context of human HLA-A2 
expressed in HLA-A2.  Even with the thousands of peptide/HLA-A2 complexes 
available on healthy cells of the HLA-A2 transgenic SCID mouse, the Fab still 
accumulated at the transplanted tumors.  This is especially interesting considering 
that the sequence of the peptide E75 from HER2/neu is identical to that found in 
mouse epidermal growth factor receptor 2 [93] and that the HLA-A2 expression in 
the HLA-A2 transgenic mouse model is expressed at comparable levels to H-2Db in 
thymus, bone marrow, and spleen [94].  The dynamic scans showed initial rapid 
accumulation of 64Cu- DOTA-fE75 followed by a steady-state in all the tissues (liver, 
kidney, humoral muscle, and control tumor) except for the HLA-A2 positive tumor 
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similar to the SCID mouse experiments.  It is not clear why we did not see 
accumulation of the Fab in sites other than the tumor and those predicted by the 
injection of this sized protein.  Although the mouse antigen presenting machinery 
can process and present peptides recognized by human HLA-A2-restricted T cells 
[93], it is possible that there are differences that preclude presentation of the E75 
peptide or that the expression level is so much lower in normal cells that there is a 
very small dilution of the signal compared to the tumor.     
Theoretically, the best in vivo images of the 64Cu-DOTA-Fab accumulation 
would occur after removal of the unincorporated label, but the half-life of fE75 
binding to E75/HLA-A2 measured by SPR is on the order of minutes and due to the 
high vascularization of the tumors, the Fab is removed readily.  We conclude that all 
of these Fab sized probes of roughly 55 kDa could be highly specific and bind very 
tightly, but they do not have a long enough half-life to be useful on their own unless 
they are endocytosed by the cell.  The signal could be greatly increased by 
multimerization of the Fab [95,96].  However, this problem does not diminish the 
significance of the observation that the Fab targeting was successful even in the 
context of transgenic expression of HLA-A2 in all the cells of the mouse. 
Antibodies specific for pMHC are useful tools for understanding antigen 
presentation in vivo and allowing targeted therapy for cancer.  Not only can they be 
used to directly visualize T-cell epitopes [45,90,97], they can aid in method 
development for peptide-based immunotherapy, where visualization of a particular 
pMHC before and after treatment would be beneficial.  This can include analysis of 
intracellular generation, trafficking, cell surface expression, and stability of pMHC 
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complexes on antigen presenting cells (APC).  Antibody fragments with pMHC 
specificity can improve on the successes of adoptive T-cell therapy.  Even though up 
to 50% of patients treated with ex vivo expanded tumor-infiltrating lymphocytes show 
clinical responses [70,98], it is not possible to produce significant quantities of tumor 
infiltrating T cells from all cancer patients due to the inability to either isolate or 
expand them in vitro.  There is promise in the field of genetically modified T-
lymphocytes, where TCR-like antibodies are transferred to T lymphocytes via 
retroviral infection for their expression on the T cell surface [99].  T cells expressing 
tumor-specific receptors, chimeric antigen receptors and modified TCRs specifically 
killed tumor cells and had antitumor effects in vivo [100-103]. 
In summary, we have demonstrated that pMHC specific Fabs can be quickly 
and efficiently isolated from our skewed bacteriophage library. These particular Fabs 
provide much greater stability and higher affinity than would T cell receptors making 
them particularly good imaging agents.  One of the Fabs, fE75, shown to have high 
affinity and high specificity, was derivitized as an in vivo imaging agent and 
selectively localized to HLA-A2 positive tumors in SCID HLA-A2 transgenic mice.  It 
is anticipated that phage display-derived TCR-like antibody fragments have a wide 
range of applications in research, diagnostic, and therapeutic applications.   
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Chapter 3 
T Cell Receptor-like Antibody Fragment Binds to Insulin Secreting Beta Cells 
in vivo 
  
 
3.1  Introduction 	  
All autoimmune diseases share one common feature, the breaking of T cell 
tolerance.  A common feature of autoreactive T cell stimulation is the interaction of 
the T Cell Receptor (TCR) with peptide-bound Class I Major Histocompatibility 
Complex (pMHC).  Upon binding the pMHC, autoreactive T cells undergo a 
multitude of changes, resulting in proliferation, cytokine release and recruitment 
other immune cells inherent to disease progression.  Collectively, this process either 
indirectly (class II MHC-mediated) or directly (class I MHC-mediated) leads to the 
death of the targeted endogenous cells, such as beta cells in the context of type I 
diabetes (T1D).  Importantly, the interaction of specific antigenic peptides with 
disease-associated MHC is required for autoimmune disease.  In addition, disease 
associated MHC allotypes may only differ in sequence by one or two amino acids in 
comparison to non-disease associated counterparts, while leading to drastic 
changes in the reactivity or selection of peptides that bind (1, 2).  Despite this, the 
development of pMHC based therapeutics has been hindered due to the lack of 
knowledge concerning the range of pMHC presentation during autoimmunity and the 
overall contribution of different pMHC to autoimmune cell activation (3).   
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To directly monitor disease-associated pMHC on targeted cells during 
autoimmunity, an ideal reagent would allow the tracking of specific pMHC antigens, 
while having the same specificity as an autoreactive TCR.  With this in mind, the use 
of recombinant TCRs have been tested, but have proven to be difficult to produce 
recombinantly and have relatively low affinity (high micromolar range) (4-9).  In 
contrast, monoclonal antibodies are relatively easy to produce in bulk once the 
correct hybridoma is created and may have high affinity.  However, generating these 
hybridomas has proven very difficult for most labs for unknown reasons. 
TCR-like antibody-based molecules have improved understanding of antigen 
presentation in melanoma and hepatitis B viral infections (10-12), been used as 
immunotherapies against tumors (13), and targeted drug delivery for hepatitis B 
virus-infected cells (14).  Phage libraries have been successfully used to select 
TCR-like molecules, mostly as antibody fragments (Fab) or single chain variable 
domain fragments (scFv), with nanomolar binding affinity for specific pMHC (15-17).  
However, monoclonal antibodies generate immune responses because of the Fc 
portion of the antibody via complement or Fc receptor mediated immune cell 
activation.  This could be highly problematic, especially in the context of 
autoimmunity.  Therefore, it would be better to use a TCR-like molecule without an 
Fc portion such as an antibody fragment (Fab) or dimer of Fab (Fab2) for these 
cases.   Previously, we demonstrated that such a TCR-like Fab, specific for human 
epidermal growth factor receptor (HER2/neu) derived peptide E75 associated with 
HLA-A2, could localize to human tumors in vivo in HLA-A2 transgenic scid mice (18).  
The high affinity and specificity of these TCR-like molecules suggests that similar 
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Fabs directed towards autoimmune T cell antigens may be excellent tools to study 
MHC antigen presentation in an autoimmune disease such as T1D.  
T1D is a multi-factorial disease, with known environmental and genetic 
influences.  While many immune cells are known to contribute to disease 
progression, the main mediators of beta cell destruction are autoreactive CD4+ 
helper T cells and CD8+ cytotoxic T cells (CTL).  Autoreactive CTLs recognize 
unique pMHC presented by the beta cells localized in the islets of Langerhans.  
Upon binding of the pMHC, beta cell-specific CTLs become activated, resulting in 
the destruction of the endogenous beta cell mass (19-21).  Death of the beta cells 
leads to reduced insulin production and an inability to regulate systemic blood 
glucose levels, resulting in the development of T1D once only 10-20% of the beta 
cell mass remains (19, 20).  Importantly, CTL are required for T1D development, as 
mice that lack class I MHC due to a knockout of the beta-2-microglobulin gene do 
not develop diabetes (22, 23).  As a result of this finding, searches were initiated to 
identify potential disease associated peptides presented on beta cells class I pMHC.  
Several candidate peptides were identified including:  proinsulin (24, 25), insulin (24, 
26), glutamic acid decarboxylase (27), and islet specific glucose-6-phosphatase 
catalytic subunit related protein (IGRP) (28), but the relative contribution of each 
peptide to overall disease progression is still a source of controversy.   
To better understand the role that various pMHC complexes play in the 
initiation and progression of T1D, we developed several TCR-like Fabs that bind with 
high affinity to beta cell expressed pMHC.  One of the TCR-like Fabs is specific for 
the murine MHC H-2Kd carrying a disease-associated peptide derived from islet-
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specific glucose-6-phosphatase catalytic subunit related protein, IGRP.  The IGRP 
peptide was selected due to its relevance to the non-obese diabetic mouse model 
(NOD) of T1D.  In these animals, IGRP/H-2Kd pMHC specific CTLs are part of the 
earliest islet infiltrates and the number of IGRP/H-2Kd pMHC specific CTLs in the 
peripheral blood correlates with T1D development (29-31).  Furthermore, the 
sequence of murine IGRP has strong conservation across species including humans 
(32).  In addition, we isolated another TCR-like antibody fragment specific for MHC 
H-2Kd carrying a peptide derived from influenza hemagglutinin, HA.  The Fabs 
targeting the IGRP/ H-2Kd or HA/ H-2Kd are named fIGRP and fHA respectively.  In 
addition to acting as a control for studies in the NOD mouse, the fHA Fab can be 
utilized for imaging studies in the NOD.InsHA model (33).  In this mouse line, 
influenza hemagglutinin expression is driven by the insulin 1 promoter, resulting in 
HA/ H-2Kd linked expression on the surface of beta cells.  Using these two Fabs, we 
have shown that TCR-like Fabs specifically localize to beta cells in vivo and that may 
allow for the noninvasive imaging of disease progression.  In addition, we also have 
shown that administration of fIGRP and fHA respectively can block autoreactive T 
cell interactions with the beta cell specific pMHC in vitro, suggesting a potential role 
for these molecules as an immunotherapeutic, specifically in the context of 
combinatorial therapy. 
 3.2  Materials and methods 	  
Ethics statement.  Throughout the course of the study, all guidelines and standards 
of the Association for Assessment and Accreditation of Laboratory Animal Care at 
the University of North Carolina (UNC) Animal Facility were followed. The mice were 
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cared for according to the UNC Office of Animal Care and Use. The research was 
conducted under the protocol (10-236.0) with approval by the UNC Institutional 
Animal Care and Use Committee. 
Antibodies, synthetic peptides, and reagents.  The UNC Peptide Synthesis 
Facility (Chapel Hill, NC) synthesized the peptides: IGRP (from islet specific 
glucose-6-phosphatase catalytic subunit-related protein; VYLKTNVFL, residues 206-
214) and HA (from influenza hemagglutinin; IYSTVASSL, residues 518-526).  Rabbit 
monoclonal antibody C27C9 against mouse insulin was purchased from Cell 
Signaling.  Alexa Fluor 488 conjugated goat anti-rabbit bound (A11034) and Alexa 
Fluor 647 conjugated streptavidin, Alexa Fluor 647 conjugated tyramide staining kit 
and 4’-6-diamidino-2-phenylindole (DAPI) were purchased from Invitrogen.  Anti-
fluorescein isothiocyanate (polyclonal, ab19224) was purchased from Abcam.  
PacBlue-conjugated CD4 antibody (clone RM4-5), PeCy7-conjugated CD8 antibody 
(clone 53-6.7), and FITC-conjugated CD3 (clone 145-2c11) were purchased from 
eBiosciences. APC conjugated rat anti-mouse IFN-γ antibody (clone XMG1.2) was 
purchased from BD Biosciences.   
Generation of site-specifically biotinylated pMHC complexes.  The mouse MHC, 
H-2Kd and mouse beta-2-microglobulin (β2M) were produced as inclusion bodies in 
E. coli BL21 (DE3) (Invitrogen, Inc.).  In vitro protein folding was completed as 
described previously (34).  In summary, a 10:1:1 molar ratio of peptide, β2M, and 
MHC heavy chain were injected into a folding buffer consisting of 100 mM Tris pH 
8.0, 400 mM arginine, 2 mM EDTA, 5 mM glutathione (reduced), 0.5 mM glutathione 
(oxidized).  Protease Inhibitors including PMSF, pepstatin and leupeptin were added 
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and the total final protein concentration was never greater than 50 µg/ml.  The folded 
pMHC was concentrated in an Amicon ultrafiltration cell (Millipore, Billerica, MA) 
after incubation for 24-36 hours at 10 °C. Folded pMHC was purified by gel filtration 
chromatography (Phenomenex, Inc.; Torrance, CA).  The purified pMHC molecules 
were concentrated to no greater than 3 mg/ml and stored at -80°C until use. Typical 
yield for each 1 L refold were approximately 14% at 5 mg of pMHC.  The purified 
pMHC was site specifically biotinylated with biotin ligase BirA (Avidity, LLC; Aurora, 
Colorado) according to the manufacturer’s instructions.  Purified, putatively-
biotinylated pMHC molecules were incubation with streptavidin and degree of 
biotinylation determined by gel-shift assay using non-denaturing SDS PAGE (no 
reducing agent, no heat treatment). 
Fab library construction.  The Fab library was constructed as discussed previously 
(18).  Briefly, a template plasmid consisting of a modified version of the Fab-4D5 
gene (35), where the heavy chain of the Fab is fused to the carboxyl-terminal 208 
residue segment of M13 phage pIII, was used for construction of the libraries.  Most 
residues in the H1, H2, and H3 loops were replaced with serine.  In the CDR-H3, a 
TAA stop codon and a unique BAMHI site were introduced.  A phoA promotor was 
used to control expression of both the light and heavy chain-pIII fusion proteins.  A 
custom-made trimer phosphoramidite mixture (Glen Research, Sterling, VA) was 
used to synthesize oligonucleotides encoding biased amino acid mixtures for the 
CDR-L3 and H3 (indicated in Figure 1C as “X”s).  The synthesis was completed on 
an Expedite synthesizer (ABI) according to Glen Research’s instructions.  The 
deprotected oligonucleotides were purified using acrylamide gel electrophoresis.  
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The CDR-H1 and H2 oligonucleotides were purchased from Integrated DNA 
technologies as they did not require trimer phosphoramidites.  The Kunkel 
mutagenesis method (36) was used to introduce mutations in the CDR-L3, CDR-H1, 
CDR-H2 and CDR-H3 by the oligonucleotides.  Following the first transformation of 
the SS320 cells (36), purification of the DNA for the library was completed.  The 
purified DNA library was digested with BamHI and then used to transform the SS320 
cells and produce phage particles, as described (35).  This prevented clones 
expressing non-mutated CDR-H3.  The Fab library consisted of approximately 1010 
independent clones.  
Selection of phage-displayed antibody fragments.  Isolation of phage-displayed 
Fabs was performed as previously described (35) with minor modifications.  After the 
first round of selection, the isolated phages were enriched and incubated with 
streptavidin-coated magnetic beads.  Bound phages were removed creating a 
“precleared” phage pool by incubation with streptavidin-coated magnetic beads.  
Biotinylated pMHCs were incubated with these “precleared” phages followed by 
capture of phage bound pMHCs by additional streptavidin-coated magnetic beads.  
Concentrations of pMHC used were 100, 50, 10, and 10 nM for the four separate 
selection rounds respectively.  Elution of the captured phages was done by using 
100 µl of 0.1M Gly-HCl (pH 2.1) buffer, which was immediately neutralized with 35 µl 
of 1M Tris-Cl buffer (pH 8).  The affinity of the recovered Fab expression phage were 
determined using phage ELISA and the sequence of the Fabs determined by DNA 
sequencing as described previously (35). 
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Production of soluble recombinant Fabs.  Fab expression vectors containing an 
8x histidine tag and a termination codon at the 3’ end of the heavy chain gene were 
prepared using the phage-display vectors for the isolated phage clones.  A biotin 
ligase BirA (AviTag, Avidity, LLC.) substrate tag was added to the carboxyl terminus 
of the light chain in the Fab expression vector.  Fab proteins were expressed in 
chemically competent 55244 E. coli (ATCC).  Protein A affinity chromatography 
followed by cation exchange chromatography were used to purify the Fab proteins 
as described previously (35).  Typical yields were between 2-5 mg of purified Fab 
from 1 L bacterial culture.  >90% purity was regularly obtained as measured by SDS-
PAGE analysis. 
Measurement of binding affinity of TCR-like Fab for pMHC by surface plasmon 
resonance.  All SPR experiments were conducted using a Biacore Ni-NTA sensor 
chip (GE Healthcare).  For each antibody fragment, approximately three hundred 
response units (RUs) were bound to their respective flow channels utilizing the 8x 
histidine tag on the Fabs.  Soluble class I MHC (analyte) was injected onto the chip 
surface at a flow rate of 20 µl/min in a 300s pulse.  The concentrations of injected 
pMHC ranged from 200 nM to 1 nM in two fold dilutions.  Regeneration of the NTA 
surface was completed using 0.2 M EDTA, which removed Ni and all bound protein, 
followed by recharging the surface with 0.04 M NiSO4.  Each concentration of 
analyte was injected at least three times in random order to obtain three curves for 
analysis.  The data were processed using Scrubber (BioLogic Software, Campbell, 
Australia). The SPR response curves at each concentration were double referenced 
as previously described (18, 37).  A SPR response curve fit was used and its 
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suitability at predicting the raw SPR curve was measured based on the appearance 
of residuals and χ2 values.  The predicted curves for each Fab-pMHC binding curve 
visually overlaid well with the experimental curves and the residuals were small and 
random.  χ2 was below 1 for all reported curve fits. 
Fab Tetramer Production.  Site-specific biotin-ligase BirA (Avidity, LLC; Aurora, 
Colorado) was used to biotinylate the purified Fabs according to the manufacturer’s 
instructions.  Successful biotinylation of the Fabs was confirmed by gel shift analysis 
as described above for pMHC.  Fab tetramers were made by incubating streptavidin-
HRP (Invitrogen, Inc.) with the biotinylated Fabs in a 1 to 4 molar ratio for ten 
minutes at room temperature. 
Immunofluorescence of murine pancreas sections in vitro.  Pancreata from 12-
week old NOD and C57BL/6 mice were excised, fixed in 1% paraformaldehyde for 
10 minutes and embedded in optimal cutting temperature (OCT) media (Sakura 
Finetek, Torrance, CA).  The embedded tissue was cryopreserved using an 
isopentane liquid nitrogen bath.  Pancreas tissue blocks were cut into six micrometer 
sections using a Leica CM1950 cryostat (Leica Microsystems Inc., Buffalo Grove, 
IL), placed on slides, and stored at -80 ̊ C until further use.  For immunofluorescence 
staining of the pancreas sections, the slides were warmed to room temperature and 
washed in PBS.  The alexa-Fluor-488 bound rabbit anti-mouse insulin antibody and 
the tetramer of fIGRP Fab and streptavidin-HRP were added to the pancreas section 
for two hours.  After washing in PBS, alexa fluor 647-tyramide was added to each 
section for 5 minutes and washed in PBS according to the manufacturer’s 
instructions.  Following this wash, 4’-6-Diamidino-2-phenylindole (DAPI) was added 
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to the pancreas section and then mounted using ProLong Gold antifade reagent 
(Invitrogen).  The stained tissues were analyzed on an inverted 
Fluorescence/Differential Interface Contrast (DIC) microscope (Leica Microsystems 
Inc., Buffalo Grove, IL) with Hamamatsu OrcaER camera and MicroPublisher. 
Fluorescein labeling of Fab.  TCR-like antibody fragments were labeled with 
fluorescein isothiocyanate at a 1:10 molar ratio according manufacturer’s 
instructions.  Fluorescein labeled Fab was purified from free dye by desalting column 
chromatography.  The degree of labeling was measured by absorbance and 2-3 
fluorescein molecules per Fab were regularly obtained.   
In vivo labeling of murine pancreas.  200 µL of 5 µM fluoroscein-labeled Fab in 
PBS were injected into the tail vein of 8 to 10 week old NOD or NOD.InsHA mice. 
Three hours post injection, pancreata were removed and placed in a solution of 10% 
formalin at pH 6.5 for 10 minutes, followed by tissue transfer to a solution of 10% 
formalin at pH 11 for overnight incubation at 4 ̊C.  Following incubation, the 
pancreata tissue were embedded in OCT and cryopreserved using an isopentane 
liquid nitrogen bath.  The embedded tissue blocks were cut into 6µm samples with a 
Leica CM1950 cryostat, placed on slides, and stored at -80 ̊ C until stained for 
additional markers. 
For immunofluorescence staining, the slides were warmed to room 
temperature and washed twice in PBS.  Rabbit monoclonal anti-insulin antibody and 
biotinylated anti-fluoroscein isothiocyanate (anti-FITC) were added to the pancreas 
sections for 2 hours.  After extensive washing, secondary Alexa Fluor 488 labeled 
goat anti-rabbit antibody and streptavidin bound with horseradish peroxidase (HRP) 
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were applied to the pancreas section for 1.5 hours. Visualization of the Fab on the 
pancreas sections was accomplished with Alexa-Fluor 647 tyramide according to the 
manufacturer’s instructions.  Nuclei were stained with DAPI and sections were 
mounted for analysis.  The stained tissues were analyzed on an inverted 
Fluorescence/Differential Interface Contrast (DIC) microscope (Leica Microsystems 
Inc., Buffalo Grove, IL) with Hamamatsu OrcaER camera and MicroPublisher. 
Isolation of Transgenic T cells.  Spleens from 10 week old transgenic 8.3 TCR 
expressing (38) or CL4 TCR expressing NOD mice (39) were excised and single-cell 
suspensions were prepared by grinding the tissue with frosted slides in RPMI 1640 
complete medium (Mediatech, Inc., Manassas, VA).  Red blood cells were lysed with 
red blood cell lysis buffer.  8.3 or CL4 transgenic CD8+ were purified by negative 
selection using the CD8+α isolation kit (Miltenyi Biotec) according to the 
manufacturer's instructions. 
Competition T cell assay.  Splenocytes in a single-cell suspension prepared from a 
12 week old NOD male spleen were placed in serum free RPMI 1640 medium and 
incubated with either IGRP peptide or HA peptide (1-5 µM) for four hours.  Following 
incubation, the splenocytes were irradiated and aliquoted 5 x 104 peptide-pulsed 
splenocytes per well.  Increasing concentrations of fIGRP or fHA were added to 
individual wells containing the irradiated, peptide-pulsed splenocytes for 30 minutes.  
The Fab concentrations selected were based on the KD of the given Fab.  8.3 or CL4 
TCR-transgenic CD8 T cells were added at a 1 to 1 target (peptide pulsed 
splenocyte) to effector (T cell) ratio to IGRP peptide pulsed spleen cells or HA 
peptide pulsed spleen cells respectively.  After 24 hr, supernatants were removed 
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and assayed for IFN-γ by ELISA according to the manufacturer’s instructions.  The 
remaining cells were stained for intracellular IFN-γ by flow cytometry.  Briefly, cells 
were treated with brefeldin A for 5 hrs washed twice in PBS supplemented with 2% 
bovine serum albumin and EDTA, then stained with antibodies specific for the 
surface markers CD4, CD8, and CD3.  Cells were then fixed, permeabilized and 
stained intracellularly with an antibody specific for IFN-γ overnight at 4 ̊C.  The next 
day, cells were washed in Perm/Wash buffer (BD Biosciences) and data was 
acquired using a Cyan Flow Cytometer (Cyan, Beckman Coulter, Inc.). 
Glucose Tolerance Test.  Intraperitoneal glucose tolerance tests were performed 
as previously described (40) with some modification.  11-week old NOD female mice 
were held without food for 18 hr, followed by a 200 µL tail vein injection of 5 µM 
fIGRP or PBS.  Three hours post-injection, baseline blood glucose levels were 
measured followed by an intraperitoneal injection of glucose (2g/kg mouse weight).  
Blood glucose levels were acquired at set intervals over a two-hour timeframe.   
 3.3  Results 	  
TCR-like Fabs have high affinity and specificity for cognate pMHC.  In NOD mice, 
endogenous beta cells are known to present various autoantigens on MHC I 
molecules that contribute to the development of T1D (41).  As a result, 
understanding the expression patterns of different autoantigens, both in magnitude 
and timing, may help to shed light on the role these antigens play in disease.  
Therefore, we generated sets of T cell receptor-like antibody fragments (TCR-like 
Fabs) to two different pMHC using bacteriophage-display technology (35) in order to 
track the expression of different pMHC specifically on beta cells.  The first, named 
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fIGRP, recognizes a peptide derived from the islet-specific glucose-6-phosphatase 
catalytic subunit-related protein (IGRP) bound to the class I major histocompatibility 
complex, H-2Kd.  Importantly, this complex is expressed on endogenous beta cells in 
the NOD mouse and is the target recognized by CD8+ CTL derived from the 8.3 
diabetes mouse model (38).  In addition, we generated a second H-2Kd restricted 
TCR-like Fab, fHA, specific for an influenza hemagglutinin peptide.  While acting as 
a control for studies in NOD mice, fHA also allows us to target beta cells in the 
NOD.InsHA mouse, where HA expression is driven by the insulin 1 promoter (33).  
Furthermore, similar to 8.3 cells in NOD mice, CD8+ T cells derived from the CL4 
mouse target HA and have been shown to induce T1D in transfer studies in 
NOD.InsHA recipients (39).  
 The TCR-like Fabs, fIGRP and fHA, were isolated by phage-display 
technology, which utilized a “synthetic” antibody library built on the stable 4D5 
humanized Fab scaffold (Figure 1A) (42). The mutated hypervariable loops in the 
library lack fully randomized sequences, but do have reduced complexity favoring 
serine and tyrosine in the mutated loops (H1, H2, H3, L3) (35).  Site-specific 
biotinylated pMHC, IGRP/ H-2Kd or HA/H-2Kd, were used as targets for sorting the 
Fab-expressing bacteriophage library.  After four rounds of selection, an ELISA was 
used to determine the relative binding affinity and the specificity of the amplified Fab 
expressing phage (Figure 1B).  Bacteriophages that did not bind with high affinity or 
did not bind specifically were excluded from further analysis.  Both chosen Fab-
expressing phage bound cognate pMHC, but not control pMHC.  The distinct CDR 
sequences for fIGRP and fHA were shown in Figure 1C.  The phage-display vectors  
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Figure 1:  Isolation of TCR-like Fabs by Phage Display.  Phage-display 
technology was used to isolate Fabs specific for either IGRP/H-2Kd or HA/H-2Kd.  
The stable 4D5 Fab scaffold consisting of a single heavy and a light chain each with 
a variable and constant domain was used to construct each Fab.  The amino acid 
diversity of the Complementary Determining Regions (CDR) for the light chain L3, 
and the heavy chain; H1, H2, and H3 was restricted in favor of tyrosine, serine, and 
other small amino acids (modeled from PDB ID: 1FVD) (A).    After three rounds of 
phage display selection, the specificity of the amplified clones was determined using 
an ELISA.  The Fab clones fIGRP and fHA bound IGRP/H-2Kd and HA/H-2Kd 
respectively with no detectable binding to other pMHC molecules (B). The amino 
acid sequence of each clone was determined after the ELISA specificity 
determination (C).   
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for the isolated clones were then converted into Fab expression vectors for protein 
production in E. coli (35, 43). 
 Surface plasmon resonance was used to determine the binding affinity (KD) of 
fIGRP and fHA binding to their cognate and noncognate pMHC.  As shown in Figure 
2, both Fabs bound cognate pMHC with nanomolar binding affinity.  Specifically, 
fIGRP bound IGRP/H-2Kd with a KD of 116 ± 8 nM (n=3) (Figure 2A), while fHA 
bound HA/H-2Kd with a mean KD of 24 ± 5 nM (n=3) (Figure 2D).  Levels of binding 
to non-cognate pMHC molecules was below background at concentrations up to 200 
nM using different peptide (Figure 2B and 2C) or to unrelated pMHC (data not 
shown) for both Fabs.  Therefore, these data indicate that phage display can be 
used to isolate TCR-like Fabs with high binding affinity and specificity to cognate 
pMHC. 
TCR-like antibody fragments bind beta cells.  To assess the ability of fIGRP to 
detect endogenously processed and presented IGRP/H-2Kd on beta cells in a NOD 
mouse, immunofluorescence of mouse pancreas cryosections was done (Figure 3).  
Insulin staining was used to identify islets of Langerhans in the pancreas (Figure 3A 
and 3D).  Biotinylated fIGRP was multimerized by addition of streptavidin and used 
to stain the NOD and control C57BL/6 mouse pancreas sections.  As expected, 
fIGRP staining was detected in only the NOD mouse pancreas sections (Figure 3B).  
Insulin and fIGRP colocalized across all of the islets in each pancreas section.  
Colocalization of insulin staining and fIGRP was observed on pancreas sections 
from the IGRP/H-2Kd expressing NOD islets (Figure 3C).  In contrast, no detectable 
fIGRP immunofluorescence was observed in pancreas sections from the  
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Figure 2:  TCR-like Fabs Bind Cognate pMHC with Nanomolar Affinity.  SPR 
binding response curves of pMHC, IGRP/H-2Kd, binding IGRP/H-2Kd specific Fab, 
fIGRP (A) and HA/H-2Kd specific Fab, fHA (C) and pMHC, HA/H-2Kd, binding fIGRP 
(B) and fHA (D) are shown.  Each Fab was immobilized onto individual flow 
channels in an NTA-Ni chip.  Kinetic data for each Fab binding each pMHC molecule 
were globally curve fit as a bimolecular reaction.  Green and blue lines designate the 
start and end respectively of each pMHC injection. Binding curves and curve fits are 
drawn in black and orange respectively.  Each binding curve represents a different 
concentration of pMHC beginning at 200 nM for fIGRP and 50 nM for fHA and 
decreasing in 2 fold dilutions.  Specific binding was only observed between each 
Fab and its cognate pMHC i.e. fIGRP binding IGRP/H-2Kd and fHA binding HA/H-
2Kd.  The Fab, fIGRP, bound IGRP/H-2Kd with a KD of 116 ± 8 nM (n=3).  The Fab, 
fHA bound HA/H-2Kd with a mean KD of 24 ± 5 nM (n=3).  No binding above 
background was observed for either Fab binding non-cognate pMHC molecules up 
to 200 nM.   
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Figure 3:  TCR-like Fab binds to insulin producing cells in pancreas 
cryosections.  Immunofluorescence staining of representative pancreatic islets in 
12-week old male NOD (A,B,C) and C57BL/6 (D,E,F) mice using TCR-like Fab, 
fIGRP, specific for IGRP/H-2Kd.  Mouse pancreas were placed in OCT medium and 
cryofrozen using isopentane and liquid nitrogen. Tissue blocks were cut in 6 µm 
sections, fixed in 1% paraformaldehyde, and stained with primary antibodies rabbit 
anti-mouse insulin and tetramer consisting of biotinylated TCR-like Fab, fIGRP and 
streptavidin-HRP. Invitrogen Tyramide signal amplification kit was utilized for 
developing the fIGRP-streptavidin-HRP staining.  Tissues were viewed with an 
inverted Leica fluorescence microscope with digital cameras at a 40x magnification.  
Insulin staining alone was shown in A and D, fIGRP staining alone was shown in B 
and E.  The overlay of insulin, fIGRP, and Dapi was shown in C and F.   
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control C57BL/6 mouse, which expresses the H-2Kb, not the H-2Kd MHC haplotype 
(Figure 3E and 3F).  Collectively, these studies show that fIGRP is highly specific for 
IGRP/H-2Kd expressed on endogenous NOD beta cells. 
TCR-­‐like	  antibody	  fragments	  accumulate	  on	  pancreatic	  beta	  cells	  in	  vivo.  To 
investigate the ability of TCR-like Fabs to act as a diagnostic imaging tool, the 
accumulation of fIGRP and fHA on beta cells in situ was measured.  8-10 wk old 
NOD mice were injected in the tail-vein with either fIGRP or a control Fab, fE75, 
which uses the same Fab scaffold, but a different set of CDR loops (18).  Three 
hours post Fab injection, the pancreata were harvested, cryopreserved, sectioned, 
and stained for insulin and the presence of TCR-like Fab. Insulin staining was used 
to identify islets of Langerhans in the pancreas (Figure 4A and 4D).  Insulin is a 
secreted peptide hormone from the beta cells.  Therefore, the staining for insulin is 
diffuse and surrounds the beta cells.  Importantly, the only TCR-like Fab 
accumulation was in the NOD mice injected with fIGRP (Figure 4B).  Furthermore, 
the overlay of insulin and the fIGRP staining indicated that fIGRP was binding 
specifically to insulin secreting beta cells (Figure 4C).   
To assess if TCR-like Fab accumulation would occur with other islet-specific 
antigens, the accumulation of fHA on NOD.InsHA beta cells was measured.  Again, 
insulin staining was used to identify the islet of Langerhans (Figure 4G and 4J).  
Similar to the fIGRP in NOD mice, the only detectable fHA binding was observed on 
the HA/H-2Kd expressing islets from NOD InsHA mice (Figure 4H), with no staining 
observed in control HA/H-2Kd negative NOD islets (Figure 4K).  In addition, the 
colocalization of insulin and fHA again indicated specificity of the Fab for  
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Figure 4:  TCR-like Fabs accumulate on beta cells when injected in vivo.  
mmunofluorescence staining of representative pancreatic islets in 8-10-week old 
male NOD mice using TCR-like Fab, fIGRP, specific for IGRP/H-2Kd (A,B,C) or 
control TCR-like Fab, fE75, specific for E75/HLA-A2 (D,E,F) and representative 
pancreatic islets in 12-week old male NOD insHA (G,H,I) and control NOD (J,K,L) 
mice using TCR-like Fab, fHA, specific for HA/H-2Kd.  Fabs were injected into the 
mice via tail-vein.  Mouse pancreata were harvested 3 hr post injection, fixed, 
cryopreserved, and sectioned.  Tissue sections were stained for insulin and TCR-like 
Fab. Tissues were viewed with an inverted Leica fluorescence microscope with 
digital cameras at a 40x magnification.  Insulin staining alone was shown in A, D, G, 
and J; TCR-like Fab staining alone was shown in B, E, H, and K.  The overlay of 
insulin, TCR-like Fab, and Dapi was shown in C, F, I, and L.   
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endogenous beta cells.  Single stain controls are shown in Supplemental Figure 1.  
For both Fabs, clear staining was observed around islets structures and nowhere 
else.  Furthermore, all islets analyzed on numerous tissue sections for both the 
fIGRP injected NOD and the fHA injected NOD ins HA mice showed positive staining 
and accumulation around the insulin producing beta cells.  Further examples of other 
islets imaged are shown in Supplemental Figure 2.  Notably, non-specific 
immunofluorescence from both fIGRP or fHA was below detection in regions that did 
not stain insulin positive.  Together, these data demonstrate that different TCR-like 
Fabs, which bind to specific for beta cell pMHC, can traffic to and accumulate in 
detectable amounts in endogenous NOD islets. 
TCR-like Fabs block autoreactive T cell interaction with beta cell specific 
pMHC in vitro.  Autoreactive CTL recognition of beta cell pMHC is a key factor in 
development of T1D (19-23).  As a result, disruption of the beta cell pMHC binding 
by the cytotoxic T cell could prevent disease onset by dampening CTL activation and 
subsequent beta cell destruction.  One way in which CTL engagement of beta clel 
pMHC could be manipulated is through blocking studies utilizing the TCR-like Fabs, 
fIGRP and fHA.  Therefore, to determine if pre-treatment with fIGRP or fHA could 
dampen the activation of antigen specific CTL in vitro, splenocytes were isolated 
from H-2Kd expressing NOD mice and were incubated with IGRP or HA peptides 
respectively, to mimic a beta cell pMHC.  After pusling, these splenocytes were co-
cultered with 8.3 or CL4 TCR-transgenic CD8+ T cells (specific for IGRP/H-2Kd or 
HA/H-2Kd pMHC respectively) and increasing concentrations of fIGRP or fHA TCR-
like Fab.  After twenty-four hours, interferon-gamma (IFN-γ) synthesis from activated 
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CTLs was measured in two ways:  1) by ELISA of supernatants (Figure 5) and 2) by 
intracellular IFN-γ staining by flow cytometry (Supplemental Figure 3).  Detectable 
IFN-γ production inversely correlated with TCR-like Fab concentration in an antigen 
specific manner (i.e. fIGRP and IGRP peptide, fHA and HA peptide).  By ELISA, the 
EC50 of fIGRP for the blockade of IFN-γ production by 8.3 T cells was 592 ± 50 nM 
(n=3) (Figure 5A).  Alternatively, fHA had an EC50 of 314 ± 40 (n=3) for blockade of 
IFN-γ production by CL-4 T cells (Figure 5D).  Importantly, no significant decrease in 
IFN-γ was observed when TCR-like Fabs were incubated with spleen cells 
expressing the noncognate pMHC (Figure 5B and 5C).  Similar trends were 
observed by intracellular staining of IFN-γ by flow cytometry (Supplemental Figure 
3).  Collectively, these data show that the TCR-like Fabs can block IFN-γ production 
in an antigen specific manner in vitro. 
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Figure 5:  TCR-like Fabs block recognition by autoreactive T Cells.  Spleen cells 
from NOD mice were incubated with either IGRP peptide (A, B) or HA peptide (C,D) 
for four hours. Increasing concentrations of fIGRP or fHA were added to the peptide 
pulsed spleen cells for 30 minutes.  Following incubation, 8.3 or CL4 TCR-transgenic 
CD8 T cells were added at a 1 to 1 target to effector ratio to IGRP peptide pulsed 
spleen cells or HA peptide pulsed spleen cells respectively.  After 24 hr, 
supernatants were removed and assayed for IFN-gamma by ELISA.  The Fab 
concentrations selected were based on the KD of the given Fab.  The black line is 
the curve fit for one-to-one competitive binding.  95% confidence intervals are shown 
as dotted lines.  95% confidence interval could not be determined in B because it did 
not converge.    
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Supplemental Figure 1:  TCR-like Fabs accumulate on beta cells when injected 
in vivo single staining controls.  Immunofluorescence staining of representative 
pancreatic islets in 8-10-week old male NOD or NOD ins HA mice using TCR-like 
Fab, fIGRP, specific for IGRP/H-2Kd (A, B, C, and D) or TCR-like Fab, fHA, specific 
for HA/H-2Kd (E, F, G, and H).  Fabs were injected into mice via tail-vein.  Mouse 
pancreas were harvested 3 hr post injection and were prepared by placing in 
formalin pH 6.5 followed by formalin pH 11.0.  After fixation, mouse pancreas were 
placed in OCT medium and cryopreserved using isopentane and liquid nitrogen.  
Tissue blocks were cut in 6 µm sections and stained with primary antibodies rabbit 
anti-mouse insulin and anti-FITC.  Invitrogen Tyramide signal amplification kit was 
utilized for developing the biotin and FITC labeled TCR-like Fab staining.  Tissues 
were viewed with an inverted Leica fluorescence microscope with digital cameras at 
a 40x magnification. TCR-like Fab staining alone was shown in A, C, E, and G.  The 
overlay of TCR-like Fab and Dapi was shown in B, D, F, and H.  No binding of 
control Fab fE75 or fHA in NOD mice was detected.    
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Supplemental Figure 2:  TCR-like Fabs accumulate on beta cells when injected 
in vivo.  Immunofluorescence staining of representative pancreatic islets in 8-10-
week old male NOD mice using TCR-like Fab, fIGRP, specific for IGRP/H-2Kd (A, B, 
C, G, H, I) or control TCR-like Fab, fE75, specific for E75/HLA-A2 (D, E, F, J, K, L) 
and   representative pancreatic islets in 12-week old male NOD insHA (M,N,O) and 
control NOD (P, Q, R) mice using TCR-like Fab, fHA, specific for HA/H-2Kd.  Fabs 
were injected into mice via tail-vein.  Mouse pancreas were harvested 3 hr post 
injection and were prepared by placing in formalin pH 6.5 followed by formalin pH 
11.0.  After fixation, mouse pancreas were placed in OCT medium and 
cryopreserved using isopentane and liquid nitrogen.  Tissue blocks were cut in 6 µm 
sections and stained with primary antibodies rabbit anti-mouse insulin and anti-FITC.  
Invitrogen Tyramide signal amplification kit was utilized for developing the biotin and 
FITC labeled TCR-like Fab staining.  Tissues were viewed with an inverted Leica 
fluorescence microscope with digital cameras at a 40x magnification.  Insulin 
staining alone was shown in A, D, G, J, M, and P; TCR-like Fab staining alone was 
shown in B, E, H, K, N, and Q.  The overlay of insulin, TCR-like Fab, and Dapi was 
shown in C, F, I, L, O, and R.   
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Supplemental Figure 3:  TCR-like Fabs block intracellular interferon-gamma 
production of autoreactive T cells.  Spleen cells from NOD mice were incubated 
with either IGRP peptide (A, B) or HA peptide (C,D) for four hours. Increasing 
concentrations of fIGRP or fHA were added to the peptide pulsed spleen cells for 30 
minutes.  Following incubation, 8.3 or CL4 TCR-transgenic CD8 T cells were added 
at a 1 to 1 target to effector ratio to IGRP peptide pulsed spleen cells or HA peptide 
pulsed spleen cells respectively.  After 24 hr, the cell mixtures were stained for T cell 
surface expression markers (CD3 and CD8) and intracellular interferon-gamma 
expression and analyzed by flow cytometry.  The Fab concentrations selected were 
based on the KD of the given Fab.  The black line is the curve fit for one-to-one 
competitive binding.  95% confidence intervals are shown as dotted lines.  95% 
confidence interval could not be determined in C because it did not converge.    
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3.4  Discussion 	  
Over the past 20 years, our understanding of the critical events that lead to 
the initiation and progression of T1D has vastly improved.  While many diabetic 
patients are living longer, healthier lives, there is still no cure for T1D.  As a result, 
there is a critical need to better understand the triggering factors of the disease to 
assist in the development of effective therapeutics.  In addition, while assessment of 
autoantibody production and family history has contributed to early diagnosis of the 
disease, there remains a glaring absence of reagents for noninvasive beta cell 
imaging.  Such a reagent would allow for quantitative measurements and spatial 
visualization of individual patients’ beta cell mass to evaluate either progression of 
disease and/or response to treatment.  Currently, the only method to accurately 
quantitate beta cell mass is via autopsy.  Although Magnetic Resonance Imaging 
(MRI) and Computed Tomography (CT) can identify the pancreas with a spatial 
resolution of approximately 100 micrometers, these techniques cannot identify the 
islets of Langerhans, which only represent 2-3% of the pancreatic tissue.  Diagnostic 
equipment such as Positron Emission Tomography (PET) and CT can provide the 
needed high sensitivity and spatial resolution, but the equipment’s detection of 
specific cells requires an agent that will selectively target beta cells.  The 
sulfonylurea receptor 1 and monoamine transporter 2 (44), and glucagon-like 
peptide 1 (45) have been used for PET imaging, but these imaging agents bind to 
other cell types thereby increasing background noise.  To overcome these hurdles, 
we are developing an approach that will be of great value to research and 
diagnosis/treatment to 1) identify where and when beta-cell-specific autoantigens 
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are presented to autoreactive T cells and 2) image beta cells specifically. 
Our approach to these issues began with the understanding that islet reactive 
CTL recognize a complex on the plasma membrane of beta cells comprised of a 
beta cell-specific peptide bound to a Major Histocompatibility Complex (MHC) (46, 
47).  In addition, both antigenic peptides (24-28) and the particular MHC allotypes 
(48-51) are critical to development of T1D.  Therefore, since the pMHC targeted by 
the immune system is specific, a reagent that mimics a given TCR found on islet-
reactive CTL could be utilized to assess the expression of unique pMHC on 
endogenous beta cells.  
As a result, we developed TCR-like antibody fragments that mimic the 
autoreactive TCR specific for pMHC found on NOD beta cells.  Since isolation of 
monoclonal antibodies that target specific pMHC have proven very difficult by 
traditional methods, we used an antibody fragment formatted phage display library to 
isolate TCR-like Fabs specific to beta cell pMHC.  Fabs confer numerous 
advantages over TCRs including higher affinities, ease of production and 
manipulation, and greater stability (52, 53).  Additionally, Fabs are superior to 
traditional antibodies for imaging and therapy due to a reduced total size (~54 kDa) 
and the absence of a fragment crystallizable (Fc) region.  The small size of Fabs 
allows faster and greater tissue penetration, while the lack of an Fc region dampens 
potential immunity against the antibody itself, a particularly important issue in the 
context of imaging beta cells in diabetic patients (54, 55).  Monoclonal antibodies 
with TCR specificity have previously been generated from bacteriophage libraries 
and recent improvements to isolation protocols have increased binding affinities into 
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the nanomolar range (56).  Our synthetic phage library demonstrates that nanomolar 
affinity antibodies (Figure 1) can be selected without the need for affinity maturation.  
Using immunofluorescence, our T1D TCR-like antibody fragments were able 
to specifically identify beta cells within the pancreas.  Importantly, both Fabs were 
highly selective for beta in vivo, despite exposure to thousands of other peptide/H-
2Kd complexes while traveling from the vasculature of the tail vein to the pancreas.  
While specificity of these TCR-like Fabs has been established, the ability to use 
these reagents for noninvasive imaging in vivo is still an outstanding question.  One 
potential pitfall, however, is that the monomeric Fab has a half-life of approximately 
one minute, precluding significant accumulation in the pancreas.  Therefore, 
multimerization may be required for suitable imaging in future studies.  If successful, 
accurate imaging of the beta cell mass in at-risk patients could allow for improved 
diagnosis, as well as for more effective development and evaluation of treatment 
strategies for T1D.  Furthermore, the ability to specifically target the beta cell mass 
in vivo may improve the localized accumulation of therapeutics to dampen the 
autoreactive response and restore beta cell mass (57-60).  
In addition to acting as imaging reagents, TCR-like Fabs may have potential 
as an immunotherapeutic.  We showed that both fIGRP and fHA can block the 
activation of antigen specific CTL in vitro, as determined by targeting Fabs reduced 
IFN-γ secretion (Figure 5).  While current immunotherapies for T1D have attempted 
to dampen the autoimmune response, these treatment regimens often suffer from 
short- and long-term toxicity with limited long-term benefit.  Restoration/regeneration 
of the beta cell mass has been attempted by islet transplantation with some short-
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term success, but this procedure is costly and requires continuous 
immunosuppression to prevent organ rejection (58-63).  Furthermore, adding 
exogenous beta cells without first dampening the autoimmune response is ill-
advised.  Currently, promising Phase III clinical trials are underway for two anti-CD3 
antibodies that target all T cells for improved T1D prognosis.  While stabile insulin 
production has been observed, cessation of treatment results in repopulation of the 
patient with autoreactive T cells (64, 65).  In addition, loss of all T cells is problematic 
and can leave the patients open to recurrent opportunistic infections.  Alternatively, 
our approach targets only the autoreactive T cells, by preventing the interaction of 
beta clel specific T cells with beta cell pMHC.  Surprisingly, as we show here and 
others have shown, Fabs with nanomolar binding affinities for pMHC can 
competitively block T cell interaction with the target (66), while leaving the rest of the 
immune system unmanipulated.  As a result, future studies will seek to address the 
functionality of these Fabs as therapeutics when given to p re-diabetic and recent 
on-set diabetic NOD mice. 
 In summary, we have demonstrated that TCR-like Fabs specific for beta cell 
pMHC can be isolated from a bacteriophage library.  These Fabs have high affinity 
for cognate pMHC and effectively traffic to, and bind endogenous beta cells in vivo.  
Furthermore, both fIGRP and fHA block the activation of CTL in vitro in an antigen 
specific manner.  As a result, TCR-like antibody-based molecules could be used in a 
multitude of applications.  First and foremost, treatment with TCR-like Fabs can 
allow direct visualization of antigen presentation on host cells, improving studies 
concerning where and when specific autoantigens are presented and by which cell 
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types during the progression of T1D.  Moreover, as shown in our research, TCR-like 
Fabs could be utilized as an immunotherapy for dampening the engagement and 
activation of autoreactive T cells in various autoimmune diseases. 
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Chapter 4 
The Future Applications of T Cell Receptor-Like Molecules 
 
4.1  Introduction   
 
 The most promising technologies under development to deliver therapeutics 
involve nanoparticles.  Regardless of whether those nanoparticles are lipid based or 
some other formulation, all would benefit from some way to target them to the 
correct/most optimal biological location.  Peptide-associated major histocompatibility 
complex (pMHC) molecules are promising markers to deliver such particles for 
treatment of cancer, viral, and autoimmune diseases. Recent advances using 
phage-display technology have improved the generation of T cell receptor (TCR)-like 
antibody-derived molecules targeting a wide variety of pMHC molecules.  These 
TCR-like proteins have strong binding affinities and high specificity for their cognate 
pMHC.  Therefore, TCR-like molecules have been utilized to understand antigen 
presentation in tumors, virus-infected cells, and professional antigen presenting 
cells.  Moreover, TCR-like molecules have the potential to assist 
immunotherapeutics by targeting drugs to sites of disease.  We have shown as proof 
of concept that high affinity (nanomolar) and high specificity TCR-like antibody 
fragments can be isolated by phage display and used for imaging of human 
epidermal growth factor receptor (HER2/neu) positive tumors and imaging of non-
obese diabetic (NOD) mouse beta cells in type 1 diabetes.  The next stage of 
research with TCR-like protein molecules is to further the understanding of antigen 
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presentation in disease, improvement of immunotherapeutic targeting, and to apply 
these TCR-like proteins to aid other medical research fields including nanoparticle 
delivery.   
4.2  Probing antigen-presentation 	  
TCR-like antibody-derived proteins provide a tool to study presentation in the 
immune system.  Development of effective vaccines and immunotherapies depends 
on a thorough understanding of the immune mechanisms responsible for disease 
prevention.  The advent of recombinant pMHC molecules complexed to form 
tetramers has provided a means to track sets of T cells with known antigen 
specificity (1).  These tetramers allow researchers to study the frequency of T cells 
upon immunization and/or disease, but a major part of the immune system picture 
that has been missing is a measure of the antigen presentation by antigen 
presenting cells (APCs).  Numerous studies have demonstrated that the route of 
antigen administration to experimental animals is significant in eliciting an effective 
immune response (2-4).  The effectiveness of the response is hypothesized to be 
due to the antigen trafficking to the nearest lymph node and dependent on the 
specific type of APCs utilized.  Until now, there were not useful tools to monitor in 
vivo antigen presentation after antigen administration.  By utilizing TCR-like proteins, 
vaccine formulations can be improved and an enhanced picture of antigen 
presentation can be established.  For example, Sousa and Germain used a TCR-like 
antibody specific for hen egg lysozyme (HEL) bound to I-Ak to analyze adjuvant 
function on HEL antigen presentation and the tissue distribution of APCs in mice.  
The results suggest that bacterial adjuvants, such as endotoxin, promote T cell 
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immunity by mobilizing antigen specific and activate dendritic cells to secondary 
lymphoid tissue for activation of a T cell response (5).  Moreover, antigen specific 
tolerance induction by intravenous injection of soluble proteins is shown to be due to 
the interaction of antigen specific pMHC bearing B cells with naïve antigen-specific T 
cells (6).  Application of TCR-like antibody-derived molecules for effective vaccine 
development for cancer, human immunodeficiency virus (HIV) infection, tuberculosis 
(TB) infection, and severe acute respiratory syndrome (SARS) are just a few of the 
many diseases that would benefit from TCR-like molecules.   
4.3  Improving cancer therapeutics with TCR-like molecules  	  
 We have shown that highly specific and strong affinity TCR-like antibody 
fragments can be used for positron emission tomography/computed tomography 
(PET/CT) imaging of xenotransplanted human tumors in mice (7).  A major 
drawback of our studies is that the signal to noise could not be optimized because of 
the relatively short half-life of binding of the TCR-like Fab.  If the half-life could be 
increased, the signal will accumulate and the non-specific signal (noise) will 
decrease.  One way that we can increase the time of association is to increase the 
valency of binding.  We are attempting to do that now.  Once in hand, our future 
research will involve identifying/quantifying the expression hierarchy of T cell 
epitopes present on cancer cells as a function of disease progression or therapy.  
Reiter et al. have identified expression hierarchies of melanoma tumor-associated 
antigens, but their work relied on cell lines and histology for quantitation instead of 
noninvasive in vivo imaging (8). Upon understanding the pMHC expression levels 
during a cancer’s life cycle, stage-specific cancer therapeutics can be developed 
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and targeted using the TCR-like proteins.  High affinity TCR-like antibody-derived 
molecules, usually in the nanomolar to picomolar range, allow longer association 
times on cells expressing the cancer specific pMHC.  This increases the likelihood 
for therapeutic delivery of the drug via endocytosis and/or activation of immune 
effector mechanisms including antibody-dependent cell-mediated cytotoxicity and 
complement deposition.   
Improvement of the selection of therapeutically relevant T-cell epitopes on 
cancer cells needs to be enhanced to optimize the TCR-like antibody therapeutic 
approach.  Research has shown that monoclonal antibodies are more effective 
against high density membrane antigens on cancer cells compared to membrane 
associated antigens of lower expression densities (9).  One specific example as a 
potential target is in melanoma, where these cancer cells have high expression of 
the tyrosinase antigen (8).  This may be a very attractive target for the TCR-like 
molecule therapeutic applications.  Therefore, proteomic and mass spectrometry in 
combination with TCR-like molecules will enable a personalized medicine approach 
to cancer therapy (10).  Cocktails of multiple TCR-like antibody-derived molecules 
specific for various pMHC molecules identified from the patient specific tumor 
antigen presentation hierarchy have the potential to enhance treatment effectiveness 
even against malignant cancers that can mutate to have a decreased or absent 
expression of one or more target antigens.  Moreover, this approach and other 
therapeutic applications of TCR-like proteins need to be further tested 
experimentally with the ultimate goal of application and practice in a clinical setting.   
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One of the most significant contributions that TCR-like antibody-derived 
molecules and our work on cancer and T1D specific TCR-like antibody fragments 
can have is on targeted delivery of nanoparticles.  Nanoparticles can be loosely 
defined as particulates with at least one dimension in the 1-100 nm range.  They can 
be made by a variety of different chemistries including nanocrystalline synthesis, 
polymer synthesis, and inorganic chemistries among others (11).  They are usually 
nonspecific and rely on other features such as the enhanced retention and 
permeability (EPR) effect for efficient delivery of imaging/therapeutic agents to solid 
tumors (12).  Thus, systemic toxicity can be an issue when using nanoparticles.  Due 
to the heterogeneity of cancers, personalized disease imaging and treatments based 
on the individual patients’ unique cancer chemistry are needed.  TCR-like protein 
molecules can assist in targeting these nanoparticles for imaging or therapeutic 
effect based on the patient’s cancer proteome.  The pMHC molecule that the TCR-
like protein targets is a representation of the entire cancer cell’s proteome.  Thus, 
unique differences between individual patients’ cancers can be identified and used 
to tailor specific TCR-like molecule targeted nanoparticle therapies for imaging and 
drug delivery. 
4.4  TCR-like proteins for elucidating type 1 diabetes autoimmune mechanisms 	  
The research presented for Type 1 Diabetes (T1D) in Chapter 3 is a proof of 
concept demonstrating the TCR-like molecule technology application in autoimmune 
disease.  Our research showed that TCR-like antibody fragments can be isolated 
and used to image beta cells in T1D.  Future research will focus on when, where, 
and the quantity of pMHC molecules presented during the autoimmune disease.  
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Professional antigen presenting cells are actively involved in T1D (13).  By utilizing 
TCR-like antibody-derived proteins specific for T1D-associated pMHC, an improved 
picture of the mechanism of immune activation and development can be achieved.  
TCR-like molecules in principle are as revolutionary to the field of immunology as 
recombinant pMHC molecules were for studying TCR specific T cell populations 
(14). 
In T1D, there are still important questions to be answered regarding antigen 
presentation during disease development.  One major area is the pancreatic lymph 
node (PLN), which is believed to be essential for the initial activation of autoimmune 
T cells before their migration to the islets.  The PLN drains the acinar component of 
the pancreas and segments of the intestine (15).  Removal of the PLN by surgical 
excision from NOD mice results in loss of T cell priming and no diabetes incidence 
(16).  Moreover, proliferation of autoreactive CD4 and CD8 T cells has been 
observed in the PLN (17-20).  The main mechanism by which the PLN APC obtains 
and then presents beta cell antigens is still unknown.  TCR-like proteins specific for 
autoimmune pMHC would allow in vivo monitoring of antigen presentation as T1D 
progresses.  One hypothesis is that beta cell antigens are released from beta cells 
and/or by islet dendritic cells (DCs) and travel via the lymphatic vessels to the 
draining PLN.  Calderon and collegues hypothesize that it is the migration of islet 
DCs that sensitize the PLN as part of a normal process of DC turnover (13).  TCR-
like molecules specific for autoimmune-associated pMHC can elucidate when and 
where DC subtypes are in the pancreas and surrounding tissue during T1D 
progression.  A powerful approach to interpreting the autoimmune response in T1D 
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could be developed where TCR-like molecules are used to monitor location and 
quantification of APCs and recombinant pMHC molecules are used to identify and 
quantify specific T cell subsets during disease.  This has special promise for in vivo 
imaging and real time imaging of the autoimmune process. 
Another area of interest in T1D that TCR-like antibody-derived proteins can 
aid is the phenomenon of epitope spreading.  Research suggests that initial T1D 
onset is due to responses against the epitope from the insulin B chain 9-23 region 
followed by responses against other epitopes on insulin and other antigens during 
overt disease in NOD mice (21).  This was further supported by research involving 
transgenic mice hyper-expressing either proinsulin or islet specific glucose-6-
phosphatase catalytic subunit related protein (IGRP).  It was observed that the mice 
over expressing proinsulin did not develop insulitis even when injected with 
proinsulin or IGRP.  The IGRP over-expressing mice did not develop insulitis when 
injected with IGRP peptide, but did when given the proinsulin.  Thus, IGRP is 
hypothesized to be a secondary autoantigen compared to proinsulin and is due to 
pathogenic epitope spreading (22).  Similar hypothesizes about proinsulin in human 
T1D have been proposed where epitope spreading following proinsulin assault leads 
to GAD autoantigens (23, 24).  TCR-like molecules can be used to monitor these 
primary and secondary autoantigens to discover if there are differences in 
expression of their pMHC complexes on APCs or endogenous beta cells 
corresponding to the epitope spreading.  This would assist in understanding the 
route that epitope spreading takes and to confirm that proinsulin is the primary 
autoantigen in T1D. 
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4.5  Improving production of TCR-like proteins 
 
Another application of TCR-like proteins is understanding the biochemical 
aspects of pMHC recognition.  By x-ray crystallography, crystal structures of TCR-
like antibody fragments bound to the SIINFEKL peptide from ovalbumin bound to H-
2Kb MHC showed unique mechanisms of binding between the TCR-like antibody 
fragments and the pMHC molecule.  The modes of binding were either by contacting 
the peptide directly, similar to a TCR, or by identifying unique pMHC conformations 
(25, 26). The TCR-like protein generation procedure can be improved by such 
information. TCR-like binding of TCR-like molecules would be confirmed by mapping 
of residues responsible for pMHC recognition within the peptide, MHC molecule, and 
the TCR-like molecule’s corresponding residues in the complementary determining 
regions (CDRs).  Thus, residues required for specificity against a specific peptide 
could be favored when preparing the phage display library enabling more CDR loop 
combinations to be tested and potentially faster production of high affinity TCR-like 
proteins. 
Information on the mechanism of recognition of TCR-like antibody-derived 
molecules for pMHC can improve production of alternative formats of TCR-like 
proteins.  Most generated TCR-like molecules are antibodies or antibody fragments.  
Both these protein formats are multi-domain glycoproteins dependent on disulfide 
bonds, which cannot be made in the cytosol of microbial hosts due to the reducing 
environment.  In the world of biological engineering, alternative protein backbone 
structures are being created that are without disulfide bonds or glycosylation sites, 
are thermostable, and are five to ten times smaller in molecular weight as a single-
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domain protein (27).  Potential protein scaffolds that could be screened by phage 
display include affibodies, cysteine knot proteins, and DARPins.  Affibodies are 
~6kDa three-helix bundles of 58 amino acid residues.  They are cysteine-free and 
are a natural immunoglobulin-binding domain resulting in the potential for high-
affinity complexes on the surface-exposed residues on the helices (28).  Affibodies 
against the human epidermal growth-factor receptor 2 (HER2) have been isolated 
with picomolar affinity (29).  Cysteine knot peptides are 30-50 amino acid proteins 
that are produced by solid phase polypeptide synthesis avoiding the periplasm of E. 
coli.  These molecules have a high degree of thermal and proteolytic stability (30).  
Designed ankyrin repeat proteins (DARPins) are hypothesized to work the best as 
an alternative format as a TCR-like molecule because they have loops that can be 
altered to more closely resemble the binding of a TCR.  These molecular scaffold 
proteins consist of a repeated units of a beta-turn and two antiparallel alpha helices 
with an unstructured loop leading to the repeat of this structure (31).  DARPins with 
nanomolar binding affinity for epidermal growth-factor receptor (EGFR) have been 
isolated by phage display (32).  Overall, the limitations of antibodies and antibody 
fragments have lead to alternative protein scaffolds that provide solutions to the 
problems of immunoglobulin domains.  Research will be needed to determine if such 
alternative scaffolds can be used to make a TCR-like protein with high affinity and 
specificity at a fraction of the size of regularly generated TCR-like antibodies.    
4.6  Conclusion 
 
 In summary, TCR-like molecules specific for pMHC molecules are a novel 
tool for targeting and studying antigen presentation during disease.  There is much 
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potential for the future of TCR-like molecules in elucidating the mechanisms of 
immunity and aiding in the development of effective vaccines.  Moreover, they can 
assist in effective delivery of imaging and therapeutic agents to the sites of disease.  
Before any TCR-like proteins are used in the clinic, further studies of their specificity, 
side effects and toxicity are required.  Thus, a new age of highly personalized, 
tailored medicine is in the future using TCR-like molecules to understand a patient’s 
unique cellular proteome. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   	  110	  
4.7  References 
 
1. Hansen, T. H., J. M. Connolly, K. G. Gould, and D. H. Fremont. 2010. Basic and 
translational applications of engineered MHC class I proteins. Trends Immunol. 31: 
363–369. 
 
2. Crowley, M., K. Inaba, and R. M. Steinman. 1990. Dendritic cells are the principal 
cells in mouse spleen bearing immunogenic fragments of foreign proteins. The J. 
Exp. Med. 172: 383–386. 
 
3. Guéry, J.-C., F. Ria, F. Galbiati, S. Smiroldo, and L. Adorini. 1997. The mode of 
protein antigen administration determines preferential presentation of peptide-class 
II complexes by lymph node dendritic or B cells. Int. Immunol. 9: 9–15. 
 
4. Liu, L. M., and G. G. MacPherson. 1993. Antigen acquisition by dendritic cells: 
intestinal dendritic cells acquire antigen administered orally and can prime naive T 
cells in vivo. J. Exp. Med. 177: 1299–1307. 
 
5. Reis e Sousa, C., and R. N. Germain. 1999. Analysis of adjuvant function by 
direct visualization of antigen presentation in vivo: endotoxin promotes accumulation 
of antigen-bearing dendritic cells in the T cell areas of lymphoid tissue. J. Immunol. 
162: 6552–6561. 
 
6. Zhong, G., C. R. e Sousa, and R. N. Germain. 1997. Antigen-unspecific B cells 
and lymphoid dendritic cells both show extensive surface expression of processed 
antigen–major histocompatibility complex class II complexes after soluble protein 
exposure in vivo or in vitro. J. Exp. Med. 186: 673–682. 
 
7. Miller, K. R., A. Koide, B. Leung, J. Fitzsimmons, B. Yoder, H. Yuan, M. Jay, S. S. 
Sidhu, S. Koide, and E. J. Collins. 2012. T cell receptor-like recognition of tumor in 
vivo by synthetic antibody fragment. PLoS ONE 7: e43746. 
 
8. Michaeli, Y., G. Denkberg, K. Sinik, L. Lantzy, C. Chih-Sheng, C. Beauverd, T. 
Ziv, P. Romero, and Y. Reiter. 2009. Expression hierarchy of T cell epitopes from 
melanoma differentiation antigens: unexpected high level presentation of tyrosinase-
HLA-A2 Complexes revealed by peptide-specific, MHC-restricted, TCR-like 
antibodies. J. Immunol. 182: 6328–6341. 
 
9. Mimura, K., K. Kono, M. Hanawa, M. Kanzaki, A. Nakao, A. Ooi, and H. Fujii. 
2005. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against 
esophageal squamous cell carcinoma. Clin. Cancer Res. 11: 4898–4904. 
 
10. Weidanz, J. A., P. Piazza, H. Hickman-Miller, D. Woodburn, T. Nguyen, A. Wahl, 
F. Neethling, M. Chiriva-Internati, C. R. Rinaldo, and W. H. Hildebrand. 2007. 
Development and implementation of a direct detection, quantitation and validation 
system for class I MHC self-peptide epitopes. J. Immunol. Methods. 318: 47–58. 
	   	  111	  
 
11. Bao, G., S. Mitragotri, and S. Tong. 2013. Multifunctional Nanoparticles for Drug 
Delivery and Molecular Imaging. Annu Rev Biomed Eng. 
 
12. Maeda, H., H. Nakamura, and J. Fang. 2013. The EPR effect for 
macromolecular drug delivery to solid tumors: Improvement of tumor uptake, 
lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. 
Rev. 65: 71–79. 
 
13. Calderon, B., and E. R. Unanue. 2012. Antigen presentation events in 
autoimmune diabetes. Curr. Opin. Immunol. 24: 119–128. 
 
14. Gojanovich, G. S., and P. R. Hess. 2012. Making the most of major 
histocompatibility complex molecule multimers: applications in type 1 diabetes. Clin. 
Dev. Immunol. 2012: 380289. 
 
15. Turley, S. J., J.-W. Lee, N. Dutton-Swain, D. Mathis, and C. Benoist. 2005. 
Endocrine self and gut non-self intersect in the pancreatic lymph nodes. Proc. Natl. 
Acad. Sci. U.S.A. 102: 17729–17733. 
 
16. Gagnerault, M.-C., J. J. Luan, C. Lotton, and F. Lepault. 2002. Pancreatic lymph 
nodes are required for priming of beta cell reactive T cells in NOD mice. J. Exp. 
Med. 196: 369–377. 
 
17. Tang, Q., J. Y. Adams, A. J. Tooley, M. Bi, B. T. Fife, P. Serra, P. Santamaria, R. 
M. Locksley, M. F. Krummel, and J. A. Bluestone. 2006. Visualizing regulatory T cell 
control of autoimmune responses in nonobese diabetic mice. Nat. Immunol. 7: 83–
92. 
 
18. Zhang, Y., B. O'Brien, J. Trudeau, R. Tan, P. Santamaria, and J. P. Dutz. 2002. 
In situ beta cell death promotes priming of diabetogenic CD8 T lymphocytes. J. 
Immunol. 168: 1466–1472. 
 
19. Kurts, C., R. M. Sutherland, G. Davey, M. Li, A. M. Lew, E. Blanas, F. R. 
Carbone, J. F. Miller, and W. R. Heath. 1999. CD8 T cell ignorance or tolerance to 
islet antigens depends on antigen dose. Proc. Natl. Acad. Sci. U.S.A. 96: 12703–
12707. 
 
20. Kurts, C., J. F. Miller, R. M. Subramaniam, F. R. Carbone, and W. R. Heath. 
1998. Major histocompatibility complex class I-restricted cross-presentation is biased 
towards high dose antigens and those released during cellular destruction. J. Exp. 
Med. 188: 409–414. 
 
21. Prasad, S., A. P. Kohm, J. S. McMahon, X. Luo, and S. D. Miller. 2012. 
Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 
epitope and involves functional epitope spreading. J. Autoimmun. 39: 347–353. 
	   	  112	  
 
22. Krishnamurthy, B., N. L. Dudek, M. D. McKenzie, A. W. Purcell, A. G. Brooks, S. 
Gellert, P. G. Colman, L. C. Harrison, A. M. Lew, and H. E. Thomas. 2006. 
Responses against islet antigens in NOD mice are prevented by tolerance to 
proinsulin but not IGRP. J. Clin. Invest. 116: 3258–3265. 
 
23. Ott, P. A., M. T. Dittrich, B. A. Herzog, R. Guerkov, P. A. Gottlieb, A. L. Putnam, 
I. Durinovic-Bello, B. O. Boehm, M. Tary-Lehmann, and P. V. Lehmann. 2004. T 
cells recognize multiple GAD65 and proinsulin epitopes in human type 1 diabetes, 
suggesting determinant spreading. J. Clin. Immunol. 24: 327–339. 
 
24. Narendran, P., S. I. Mannering, and L. C. Harrison. 2003. Proinsulin-a 
pathogenic autoantigen in type 1 diabetes. Autoimmun Rev 2: 204–210. 
 
25. Mareeva, T., E. Martinez-Hackert, and Y. Sykulev. 2008. How a T cell receptor-
like antibody recognizes major histocompatibility complex-bound peptide. J. Biol. 
Chem. 283: 29053–29059. 
 
26. Mareeva, T., T. Lebedeva, N. Anikeeva, T. Manser, and Y. Sykulev. 2004. 
Antibody specific for the peptide.major histocompatibility complex. Is it T cell 
receptor-like? J. Biol. Chem. 279: 44243–44249. 
 
27. Banta, S., K. Dooley, and O. Shur. 2013. Replacing Antibodies: Engineering 
New Binding Proteins. Annu Rev Biomed Eng. 
 
28. Nygren, P.-A. 2008. Alternative binding proteins: affibody binding proteins 
developed from a small three-helix bundle scaffold. FEBS J. 275: 2668–2676. 
 
29. Orlova, A., M. Magnusson, T. L. J. Eriksson, M. Nilsson, B. Larsson, I. Höidén-
Guthenberg, C. Widström, J. Carlsson, V. Tolmachev, S. Ståhl, and F. Y. Nilsson. 
2006. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. 
Cancer Res. 66: 4339–4348. 
 
30. Moore, S. J. and J. R. Cochran. 2012. Engineering knottins as novel binding 
agents.  Methods Enzymol. 503: 223-251. 
 
31. Kohl, A., H. K. Binz, P. Forrer, M. T. Stumpp, A. Plückthun, and M. G. Grütter. 
2003. Designed to be stable: crystal structure of a consensus ankyrin repeat protein. 
Proc. Natl. Acad. Sci. U.S.A. 100: 1700–1705. 
 
32. Boersma, Y. L., G. Chao, D. Steiner, K. D. Wittrup, and A. Plückthun. 2011. 
Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth 
factor receptor inhibit A431 cell proliferation and receptor recycling. J. Biol. Chem. 
286: 41273–41285. 
 
 
